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Executive Summary 
Introduction 
Health Problem 
Low back pain and neck pain are among the most frequently reported pain-
related diseases in industrial countries. Anatomically, chronic low back pain 
is localised between the costal margin and above the inferior gluteal folds, 
with or without referred leg pain that persists for at least 12 weeks, whereas 
neck pain is defined as pain located in anatomical region of the neck, with or 
without radiation to the head (cervicogenic headache), trunk and upper limbs. 
In the scope of this assessment, chronic low back pain deriving from the lum-
bar facet joints and chronic neck pain deriving from the cervical facet joints 
are the conditions of interest. Additionally, the project will focus on patients 
suffering from facet joint syndrome due to osteoporosis.  
Besides specific risk factors (e.g. infections and malignancies), most cases of 
low back pain are related to unspecific causes. For instance, smoking, obesi-
ty, physically or psychologically strenuous work, anxiety and depression have 
been identified as additional risk factors. In terms of neck pain, associations 
with degenerative changes of the lower cervical spine, musculoskeletal con-
ditions or neurological disorders have been found. 
According to current guidelines, the standard therapies include conservative 
treatments with non-steroidal antirheumatics/antiphlogistis (NSARs) and if 
available, opioid analgesics, muscle relaxants or anti-depressants. In addition, 
several non-drug therapies are recommended (including physical and behav-
ioural therapies). 
The aim of the systematic review is to evaluate the efficacy and safety of ra-
diofrequency denervation (RFD) of the cervical and lumbar facet joints in 
comparison to placebo or other non-surgical treatments in patients with or 
without osteoporosis. This report is the 1
st
 update of the systematic review 
published in 2016.  
Description of Technology 
Radiofrequency denervation is a minimally invasive procedure, which is per-
formed with local anaesthetic and mild sedation. After the facet joint is de-
termined as the source of pain, it is recommended to perform a (lateral 
branch or medial branch) nerve block, in order to verify the localisation of 
the pain.  
During the procedure, a radiofrequency generator produces an alternating 
electrical current (with a frequency of 250 to 500 kHz) through an insulated 
needle. The electric field on tip of the needle induces heat, which ultimately 
produces small lesions in the nerves suspecting of contributing to the pain. 
The technique aims to interrupt the pain signals to the brain, thus provid-
ing pain relief for 6 to 12 months. However, after that period, the nerve will 
eventually regenerate and the syndrome might return. 
RFD is a procedure and is therefore not subject to regulation. Yet, the FDA 
regulates RFD devices. Currently, there are 40 items listed under the device 
classification code for RFD generators. Since 2015, eight lesion probes have 
been approved. Out of these, four products also received CE-marking (the 
RF Puncture Generator (Baylis Medical Company Inc.), the Coolief* Cooled  
low back pain and  
neck pain are among 
most frequently 
reported conditions in 
industrial countries 
unspecific source of pain 
in most cases  
standard therapy 
includes drug- and  
non-drug regimens 
aim of the review:  
RFD against pain due  
to cervical and lumbar 
facet joint syndrome 
RFD is a minimally 
invasive procedure 
non-permanent relief  
of the syndrome 
RFD devices regulated 
by FDA/EMA  
(CE-marking) 
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Radiofrequency Kit (Halyard Health, Inc.) as well as the LCCS Disponsable 
RF Electrode and the LCCS Reusable RF Electrode (both manufactured by 
LCCS Products limited). Currently, radiofrequency denervation of the facet 
joints can be reimbursed via the Austrian DRG-system (Leistungsorientierte 
Krankenanstaltenfinanzierung) using the code AJ140 (percutaneous destruc-
tion of peripheral nerves). 
 
Methods 
The research question and the inclusion criteria of the 1
st
 assessment were 
used, except that the term sacroiliac facet joint pain was excluded. Instead, 
an additional focus was laid on facet joint pain deriving from the cervical re-
gion and facet joint syndrome in patients with osteoporosis 
A systematic literature search was carried out in several databases. Inclusion 
or exclusion of studies, data extraction and the quality assessment of the in-
cluded studies were carried out independently by two authors. The overall 
judgement on the quality of evidence was done according to the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) ap-
proach. 
Domain effectiveness 
In line with the 1
st
 assessment, randomised controlled trials (RCTs) were used 
to assess the effectiveness of RFD for facet joint pain. Additionally, non-
randomised controlled trials (NRCTs) were included. 
Following key endpoints were extracted from the studies: 
 Pain 
 Functional status 
 Global improvement 
 Health-related quality of life 
 Patient satisfaction 
 Ability to work 
Domain safety 
Accordingly, randomised controlled trials (RCTs) and non-randomised con-
trolled trials (NRCTs) were used to assess the safety of RFD for facet joint 
pain. 
Following key endpoints for safety were extracted from the studies: 
 Procedure-related complications 
 Adverse events 
 
Results 
Available evidence 
For the evaluation of cervical facet joint pain, two randomised controlled 
studies were identified, which used either a placebo/sham treatment or an 
injection with local anaesthetics as comparator. The methodological quality 
of the studies was assessed with the revised Cochrane risk of bias tool (RoB 
2.0). Out of two studies, one was assessed with a high risk of bias. 
RFD can be reimbursed 
via the Austrian  
DRG-system  
(code AJ140) 
in contrast to  
1st assessment: exclusion 
of sacroiliac facet joint 
pain, inclusion of facet 
joint pain due to 
osteoporosis 
for effectiveness and 
safety: RCTs and NRCTs 
were evaluated 
cervical facet joint pain: 
2 RCTs ; one assessed 
with a high RoB 
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For the evaluation of the clinical effectiveness of lumbar facet joint pain, we 
identified five studies that were published since the release of 1
st
 assessment. 
Among the four RCTs and one non-randomised controlled trial (NRCT), two 
studies used a placebo/sham-treatment and two studies used steroid injections 
as comparator. In one RCT, RFD combined with a standardised exercise pro-
gram was compared to a standardised exercise program alone. The risk of 
bias was evaluated applying the Cochrane RoB 2.0 tool for RCTs and the 
ROBINS-I tool for the non-randomised trial. Four out of five studies were 
judged as having a high RoB. 
An additional study (RCT) was included for the safety analysis that was 
comparing two different RFD techniques. The study was assessed with a high 
RoB. 
No studies investigating radiofrequency denervation in patients with facet 
joint syndrome due to osteoporosis were identified through the systematic 
literature search; neither did any of the included studies provide data on that 
particular topic. Therefore, results are only presented for lumbar and cervi-
cal facet joint pain. 
Clinical effectiveness 
Regarding cervical facet joint pain, no statistically significant differences were 
found in the outcomes pain intensity, functional status, global improvement 
and health-related quality of life and success of the treatment. Neither of the 
two studies reported on the outcomes ability to work or satisfaction with the 
treatment.  
Regarding lumbar facet joint pain, inconsistent results were reported across 
the studies in terms of pain intensity, functional status and global improve-
ment. The outcomes HRQoL and satisfaction with the treatment failed to 
show a significant difference between 6 weeks and 12 months. Ability to work 
was included in a composite measure (surgical Efficacy criteria of the spine 
surgery group) in one study and showed significant differences at 6 months 
post intervention.  
Safety 
Regarding cervical facet joint pain, only one study reported the outcome. In 
the placebo-controlled trial, a higher number of patients in the intervention 
group reported complications after discharge from the hospital as well as af-
ter 3 months. 
Regarding lumbar facet joint pain, no adverse events were encountered in 
three studies. A single study reported non-significant differences in the num-
ber of patients experiencing post-procedural pain. One study did not report 
on adverse events. 
Upcoming evidence 
Eight ongoing RCTs were identified in clinical trial registries, which might 
provide further data on efficacy and safety of RFD for patients with cervical 
and lumbar facet joint syndrome in comparison to alternative treatments or 
placebo (sham treatment). Out of these, one study (NCT03651804) will par-
ticularly investigate the effect of radiofrequency ablation as treatment for 
posterior element pain from vertebral compression fractures. Amongst oth-
ers, the study (with a primary completion date in March 2020) will include 
patients with osteoporosis.  
lumbar facet joint pain: 
for effectiveness,  
4 RCTs and 1 NRCT 
included 
for safety: 1 additional 
RCT included 
no evidence for facet 
joint syndrome in 
patients with 
osteoporosis 
cervical facet joint pain: 
no statistically 
significant differences 
lumbar facet joint pain: 
inconsistent results 
cervical facet joint pain: 
more complications in 
the intervention group 
lumbar facet joint pain: 
no adverse events or 
non-significant 
differences reported 
eight ongoing clinical 
trials; one study 
includes patients  
with osteoporosis 
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Discussion 
Overall, the level of evidence for the clinical efficacy of radiofrequency de-
nervation for the treatment of cervical facet joint pain is moderate to very 
low for the predefined crucial outcomes. The strength of evidence was down-
graded due to methodological deficiencies and potential imprecision of the 
effect estimates as a result of the small sample sizes. 
Regarding the clinical efficacy of radiofrequency denervation for the treat-
ment of lumbar facet joint pain, the level of evidence for the predefined cru-
cial outcomes ranged from high to low. The strength of evidence was down-
graded due to high risk of bias and inconsistencies between studies. In sum-
mary, there was some evidence that RFD for the treatment of lumbar facet 
joint pain leads to better outcomes than placebo or alternative treatments.  
Regarding the clinical efficacy of radiofrequency denervation for the treat-
ment of facet joint syndrome due to osteoporosis, no evidence was found. 
Interpretation of the findings 
Firstly, the precise localisation of the pain remains to be a major issue in 
identifying those patients that will benefit the most from the intervention. 
Thereby, studies using either two diagnostic blocks and/or aimed to achieve 
a complete or near complete reduction of pain during this process, clearly ben-
efited from the design. Secondly, the patient population varied significantly 
across the studies, especially with regard to the duration of the proceeding 
symptoms, which represents a well-known prediction factor for the anticipat-
ed response of the treatment. Thirdly, a cross-over after a specified time pe-
riod was possible in four out of eight studies. Although the study authors 
might have introduced this possibility to prevent a loss-to-follow-up, any com-
parisons after that time point have to be considered biased and thus could 
not be used for the subsequent evaluation. Finally, patients suffering from 
facet joint pain due to trauma, malignancies or inflammatory diseases were 
excluded. Thus, no conclusions can be drawn on the effectiveness of RFD 
under these circumstances. 
 
Conclusion 
The inclusion into the hospital benefit catalogue is currently not recommend-
ed. A re-evaluation is proposed in 2023. 
 
  
cervical facet joint pain: 
moderate to very low 
strength of evidence 
lumbar facet joint pain: 
high to low strength of 
evidence 
facet joint syndrome 
due to osteoporosis:  
no evidence found 
precise localisation of 
pain (via diagnostic 
block) important 
 
heterogeneous study 
populations and 
possibility of cross-over 
prevented unbiased 
results 
Currently not 
recommended 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Schmerzen im Rücken- und Nackenbereich zählen zu den häufigsten schmerz-
bedingten Erkrankungen in Industrieländern. Anatomisch gesehen sind chro-
nische Schmerzen des unteren Rückens im Bereich zwischen dem unteren 
Rippenrand und oberhalb der unteren Gesäßfalten lokalisiert, welche mit 
oder ohne verwandte Beinschmerzen einhergehen können und mindestens für 
12 Wochen anhalten. Nackenschmerzen werden als Schmerzen definiert, wel-
che sich im anatomischen Bereich des Halses befinden und in den Bereich 
des Kopfes (zervikogener Kopfschmerz), des Rumpfes oder der oberen Glied-
maßen ausstrahlen können. 
Der Fokus dieses Assessments liegt auf chronischen Schmerzen des Rücken- 
und Nackenbereiches, welche durch Störungen der Facettengelenke der Wir-
belkörper verursacht werden. Darüber hinaus konzentriert sich das Projekt 
auf jene OsteoporosepatientInnen, welche aufgrund von Schmerzsympto-
men im Facettengelenksbereich eine Behandlung benötigen. 
Neben spezifischen Risikofaktoren (z. B. Infektionen und Tumoren) gibt es 
eine Reihe von unspezifische Ursachen; bei Rückenschmerzen zählen dazu 
Rauchen, Übergewicht, körperlich oder psychisch anstrengende Arbeit, Angst-
zustände und Depressionen. Als zusätzliche Risikofaktoren bei Nacken-
schmerzen wurden degenerative Veränderungen der unteren Halswirbelsäu-
le, Erkrankungen des Bewegungsapparates oder neurologische Störungen 
identifiziert. 
Gemäß den aktuellen Richtlinien umfasst die Standardtherapie konservative 
Behandlungen mit nicht-steroidalen Antirheumatika/Antiphlogistika (NSARs) 
und, falls verfügbar, Opioid-Analgetika, Muskelrelaxantien oder Antidepres-
siva. Zusätzlich dazu werden mehrere nicht-medikamentöse Therapien (ein-
schließlich körperlicher und Verhaltenstherapien) empfohlen. 
Das Ziel dieses systematischen Reviews ist es, die Wirksamkeit und Sicherheit 
der Radiofrequenzdenervierung (RFD) der Facettengelenke im Nacken- und 
Lendenwirbelbereich im Vergleich mit Placebo oder anderen nichtoperativen 
Behandlungen bei Patienten mit oder ohne Osteoporose zu bewerten. Dieser 
Bericht ist das erste Update des 2016 veröffentlichten systematischen Reviews. 
Beschreibung der Technologie 
Die Radiofrequenzdenervierung ist ein minimal invasives Verfahren, wel-
ches unter örtlicher Betäubung und leichter Sedierung durchgeführt wird. 
Es wird empfohlen, davor eine Nervenblockade (des lateralen oder medialen 
Astes) durchzuführen, um die Schmerzquelle bestmöglich zu identifizieren. 
Während des Verfahrens erzeugt ein Hochfrequenzgenerator einen elektri-
schen Wechselstrom (mit einer Frequenz von 250 bis 500 kHz) entlang einer 
isolierte Nadel. Das elektrische Feld an der (nicht isolierten) Nadelspitze in-
duziert Wärme, welche letztendlich Läsionen durch Gewebenekrose bzw. 
Lyse in jenem Nerv hervorruft, welcher als Verursacher der Schmerzwei-
terleitung vermutet wird. Eine Schmerzlinderung kann für eine Dauer von 
6 bis 12 Monate erfolgen. Nach dieser Zeit ist die Regeneration der Nerven-
zellen jedoch abgeschlossen und die Syndrome können wiederkehren. 
Schmerzen im  
Rücken- und 
Nackenbereich in 
Bevölkerung weit 
verbreitet 
Focus des Assessments: 
chronische Schmerzen 
im Bereich der lumbalen 
und zervikalen 
Facettengelenke 
meist ausgelöst durch 
unspezifische Ursachen 
Behandlung umfasst 
medikamentöse sowie 
nicht-medikamentöse 
Therapien 
Ziel des Projektes 
RFD ist ein minimal 
invasives Verfahren 
Resultat:  
nicht-permanente 
Schmerzunterbrechung 
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RFD ist ein Verfahren und unterliegt daher in den USA keiner Regulierung. 
Jedoch müssen die verwendeten RFD-Geräte von der FDA zugelassen wer-
den. Derzeit sind 40 Produkte unter dem Geräteklassifizierungscode für RFD-
Generatoren aufgeführt. Seit 2015 wurden acht Läsionssonden zugelassen. 
Von diesen Produkten erhielten vier Produkte auch die CE-Kennzeichnung 
(der RF-Punktionsgenerator (Baylis Medical Company Inc.), der Coolief* 
Cooled Radiofrequency Kit (Halyard Health, Inc.) sowie die LCCS Dispon-
sable RF-Elektrode und die wiederverwendbare LCCS-RF-Elektrode (beide 
werden von LCCS Products Limited hergestellt).  
Derzeit kann die Radiofrequenzdenervierung der Facettengelenke über das 
österreichische LKF-System (Leistungsorientierte Krankenanstaltenfinanzie-
rung) mit dem Code AJ140 (perkutane Zerstörung peripherer Nerven) er-
stattet werden. 
 
Methoden 
Im aktuellen Assessment wurden die Forschungsfrage sowie die Einschluss-
kriterien des ersten systematischen Reviews aus dem Jahr 2016 verwendet. 
Jedoch wurden Schmerzen im iliosakralen Bereich nicht mehr berücksich-
tigt. Stattdessen wurde ein zusätzlicher Fokus auf Facettengelenksschmerz 
im Bereich des Nackens und auf das Facettensyndrom bei PatientInnen mit 
Osteoporose gelegt. 
Eine systematische Literaturrecherche wurde in mehreren Datenbanken 
durchgeführt. Einschluss oder Ausschluss von Studien, Datenextraktion und 
Qualitätsbewertung der eingeschlossenen Studien wurden von zwei Autoren 
unabhängig voneinander durchgeführt. Die Gesamtbeurteilung der Evidenz-
qualität erfolgte nach dem Grading of Recommendations, Assessment, De-
velopment und Evaluation (GRADE). 
Klinische Wirksamkeit 
Um die Wirksamkeit der RFD bei Gelenkschmerzen zu untersuchen wurden, 
in Übereinstimmung mit dem ersten Assessment, randomisierte kontrollier-
te Studien (RCTs) eingeschlossen. Zusätzlich dazu wurden nicht-randomi-
sierte Kontrollstudien (NRCTs) analysiert. 
Folgende Schlüsselendpunkte wurden aus den Studien extrahiert: 
 Schmerzen 
 Funktionsstatus 
 Globale Verbesserung 
 Gesundheitsbezogene Lebensqualität 
 Patientenzufriedenheit 
 Arbeitsfähigkeit 
Sicherheit 
Ebenso wurden randomisierte kontrollierte Studien (RCTs) und nicht-rando-
misierte Kontrollstudien (NRCTs) verwendet, um die Sicherheit der RFD 
bei Gelenkschmerzen zu untersuchen. Folgende Schlüsselendpunkte wurden 
dabei aus den Studien extrahiert: 
 Verfahrensbedingte Komplikationen 
 Unerwünschte Ereignisse 
 
Verfahren unterliegt 
keiner Regulation,  
wohl aber die 
verwendeten Geräte 
Abrechnung über  
österr. LKF-System 
(Code AJ140) 
Forschungsfrage ähnlich 
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zusätzlich zervikale 
Facettengelenke,  
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Systematische 
Literatursuche, 
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Studiendesign:  
RCTs sowie NRCTs 
berücksichtigt 
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Ergebnisse 
Verfügbare Evidenz 
Für die Beurteilung des zervikalen Facettengelenkschmerzes wurden zwei 
randomisierte kontrollierte Studien identifiziert, in denen die Intervention 
mit entweder Placebo (Schein-Behandlung) oder einer Injektion mit Lokal-
anästhetika verglichen wurden. Die methodische Qualität der Studien wurde 
mit dem überarbeiteten Cochrane-Instrument für das Risiko der Verzerrung 
(RoB 2.0) bewertet. Von zwei Studien wurde eine mit einem hohen Verzer-
rungsrisiko bewertet. 
Für die Beurteilung von Gelenkschmerzen im Bereich der Lendenwirbelsäule 
wurden fünf Studien identifiziert, die seit der Publikation des ersten syste-
matischen Reviews veröffentlicht wurden. Insgesamt wurden vier randomi-
sierte Kontrollstudien (RCTs) und eine nicht randomisierten kontrollierten 
Studie eingeschlossen. 
Von diesen verwendeten zwei Studien eine Placebo (Schein-)Behandlung und 
zwei Studien eine Steroid-Injektionen als Komparator. Eine randomisierte 
Kontrollstudie verglich den Effekt eines standardisierten Trainingsprogram-
mes mit einer Kombination aus RFD mit demselben standardisierten Trai-
ningsprogramm. Das Verzerrungsrisiko wurde mit Hilfe des Cochrane RoB 
2.0-Tools für RCTs und des ROBINS-I-Tools für die nicht randomisierte 
Studie beurteilt. Vier von fünf Studien wurden mit einem hohen Verzerrungs-
potential bewertet. 
Eine zusätzliche randomisierte Kontrollstudie, welche zwei verschiedene 
RFD-Techniken miteinander verglich, wurde in die Sicherheitsanalyse mit-
einbezogen. Die Studie wurde mit einem hohen Verzerrungspotential be-
wertet. 
Für die Beurteilung der Wirksamkeit und Sicherheit bei Osteoporose Pati-
entInnen mit Facettensyndrom konnten keine Studien identifiziert werden. 
Klinische Wirksamkeit 
Im Bereich der zervikale Facettengelenke (Nackenschmerzen) zeigte die In-
tervention keine statistisch signifikanten Unterschiede in den Endpunkten 
Schmerzintensität, Funktionsstatus, globale Verbesserung, gesundheitsbezo-
gene Lebensqualität und Behandlungserfolg. In keiner der beiden Studien 
wurde über die Endpunkte Arbeitsfähigkeit oder Zufriedenheit mit der Be-
handlung berichtet. 
In Bereich der lumbalen Facettengelenke (Rückenschmerzen) wurden von 
den eingeschlossenen Studien inkonsistente Ergebnisse für RFD in Bezug 
auf die Schmerzintensität, den Funktionsstatus und die globale Verbesserung 
berichtet. Die Endpunkte gesundheitsbezogene Lebensqualität und Zufrie-
denheit mit der Behandlung zeigten keinen signifikanten Unterschied im 
Beobachtungszeitraum zwischen 6 Wochen und 12 Monaten. Die Arbeitsfä-
higkeit wurde in einem zusammengesetzten Endpunkt (chirurgische Wirk-
samkeitskriterien der Gruppe für Wirbelsäulenchirurgie) betrachtet und zeig-
te 6 Monate nach der Intervention signifikante Unterschiede. 
zervikales Facetten-
gelenkssyndrom: 2 RCTs 
eingeschlossen;  
eine davon mit hohem 
RoB bewertet 
lumbales Facetten-
gelenkssyndrom: 5 RCTs, 
ein NRCT;  
davon 5 mit hohem  
RoB bewertet 
zervikales Facetten-
gelenkssyndrom: keine 
statistisch signifikanten 
Unterschiede 
lumbales 
Facettengelenk: 
inkonsistente Ergebnisse 
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Sicherheit 
Im Bereich der zervikalen Facettengelenke (Nackenschmerzen) berichtete nur 
eine Studie über Komplikationen: Eine höhere Anzahl von PatientInnnen in 
der Interventionsgruppe berichtete Nebenwirkungen unmittelbar nach Ent-
lassung aus dem Krankenhaus sowie nach einem dreimonatigen Beobach-
tungszeitraum. 
In drei Studien, welche RFD im Bereich der lumbalen Facettengelenke (Rü-
ckenschmerzen) untersuchten, wurden keine unerwünschten Nebenwirkun-
gen beobachtet. Eine Studie stellte nicht signifikante Unterschiede in der 
Anzahl der PatientInnen mit postoperativen Schmerzen fest. Eine weitere 
Studie berichtete nicht über diesen Endpunkt. 
Laufende Studien 
Es wurden acht laufende RCTs in klinischen Studienregistern ermittelt, wel-
che möglicherweise weitere Daten zur Wirksamkeit und Sicherheit von RFD 
für PatientInnen mit zervikalem und lumbalem Facettengelenkssyndrom im 
Vergleich zu alternativen Behandlungen oder Placebo (Scheinbehandlung) 
liefern können. In einer Studie (NCT03651804) wird insbesondere der Effekt 
der Radiofrequenzdenervierung als Behandlung von Schmerzen aufgrund von 
Wirbelkörperkompressionsfrakturen untersucht. In dieser Studie (mit einem 
primären Fertigstellungsdatum im März 2020) werden (unter anderen) Pati-
entInnen mit Osteoporose eingeschlossen. 
 
Diskussion 
Insgesamt wurde die Stärke der Evidenz zur Wirksamkeit der Radiofrequenz-
denervierung bei der Behandlung von zervikalen Facettengelenkschmerzen 
(Nackenschmerzen) für die vordefinierten entscheidenden Endpunkte als mo-
derat bis sehr niedrig bewertet. Die Beweiskraft wurde aufgrund methodi-
scher Mängel und möglicher Ungenauigkeiten der Effektschätzungen auf-
grund der geringen Stichprobengröße der einzelnen Studien herabgestuft. 
In Bezug auf die klinische Wirksamkeit der Radiofrequenzdenervierung bei 
der Behandlung von Facettengelenksschmerzen in der Lendenwirbelgegend 
(Rückenschmerzen) wurde die Stärke der Evidenz für die vordefinierten ent-
scheidenden Endpunkte als hoch bis niedrig bewertet. Die Beweiskraft wurde 
aufgrund des hohen Risikos von Verzerrungen und inkonsistenten Ergebnis-
sen der einzelnen Studien herabgestuft. Zusammenfassend gab es einige Hin-
weise darauf, dass die RFD bei der Behandlung von Facettengelenksschmer-
zen in der Lendenwirbelsäule zu besseren Ergebnissen als Placebo oder al-
ternative Behandlungen führt. 
Bezüglich der klinischen Wirksamkeit der Radiofrequenzdenervierung zur 
Behandlung des Facettengelenksyndroms aufgrund von Osteoporose konn-
ten keine Studien gefunden werden. 
Interpretation der Ergebnisse 
Die genaue Lokalisierung der Schmerzen scheint ein Hauptproblem bei der 
Ermittlung jener PatientInnen, welche am meisten von der Intervention pro-
fitieren würden, darzustellen. Studien, bei denen entweder zwei Diagnose-
blöcke verwendet wurden oder welche darauf abzielten, eine möglichst voll-
ständige Verringerung der Schmerzen während des Lokalisierungsprozesses 
zu erreichen, profitierten dabei eindeutig von diesem Design.  
zervikales Facetten-
gelenkssyndrom:  
mehr Komplikationen in 
Interventionsgruppe 
lumbales Facetten-
gelenkssyndrom:  
keine Nebenwirkungen 
bzw. nicht signifikante 
Unterschiede 
acht laufende Studien; 
eine davon inkludiert 
auch PatientInnen mit 
Osteoporose 
zervikales Facetten-
gelenkssyndrom: 
moderate bis sehr 
niedrige Stärke der 
Evidenz 
lumbales Facetten-
gelenkssyndrom:  
hohe bis niedrige  
Stärke der Evidenz 
Facettengelenks-
syndrom aufgrund  
von Osteoporose:  
keine Evidenz verfügbar 
möglichst genaue 
Lokalisation der 
Schmerzen 
entscheidend 
Zusammenfassung 
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Ein genereller Kritikpunkt der eingeschlossenen Studien waren Unterschie-
de in den Patientenpopulationen insbesondere im Hinblick auf die Dauer 
der bereits bestehenden Symptome (Schmerzen) vor der Behandlung. Es ist 
erwiesen, dass dieses Kriterium einen entscheidenden Faktor in Bezug auf 
das erwartete Ansprechen der Behandlung darstellt.  
Zusätzlich war in vier von acht Studien ein Crossover nach Ablauf eines be-
stimmten Beobachtungszeitraumes möglich. Obwohl die Studienautoren die-
se Option möglicherweise einführten, um die Compliance der Patienten zu 
erhöhen, müssen Vergleiche nach diesem Zeitpunkt als möglicherweise ver-
zerrend betrachtet werden und könnten daher nicht für nachfolgende Analy-
sen verwendet werden. 
Schließlich wurden PatientInnen mit Facettengelenkschmerzen aufgrund von 
Traumata, malignen oder entzündlichen Erkrankungen ausgeschlossen. Da-
her können keine Rückschlüsse auf die Wirksamkeit von RFD unter diesen 
Umständen gezogen werden. 
 
Empfehlung  
Die Aufnahme in den Leistungskatalog wird derzeit nicht empfohlen. Eine 
Neubewertung wird für 2023 vorgeschlagen. 
 
 
 
Unterschiede in der 
Patientenpopulation 
Crossover in  
4 von 8 Studien möglich 
Aufnahme derzeit  
nicht empfohlen 
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Summary of 2016 assessment 
In 2016, a systematic review evaluating the clinical effectiveness and safety 
of radiofrequency denervation (RFD) for sacroiliac and facet joint pain in 
patients with chronic low back pain was published by the Ludwig Boltz-
mann Institute for Health Technology Assessment (LBI-HTA) on request of 
the Austrian Federal Ministry of Health [1]. This report provides the basis 
for the current update. The following paragraphs summarise the scope, the 
results and the recommendations of the 2016 report. 
 
 
Health problem and characteristics 
of the technology 
In the scope of the assessment from 2016, chronic low back pain deriving 
from the facet or sacroiliac joints is the condition of interest. Radiofrequen-
cy denervation, a minimally invasive procedure, is used for the treatment of 
this condition. 
 
 
Scope 2016 
Is radiofrequency denervation of the facet joints or sacroiliac joint, in com-
parison to placebo or other treatments in patients with chronic facet joint 
pain or sacroiliac joint pain with a positive response to diagnostic block, 
more effective and safe concerning pain, functional status, global improve-
ment, health-related quality of life, and complications? 
The inclusion criteria for relevant studies are summarised in Table 1. 
Table 1: Inclusion criteria – Assessment 2016 
Population Second-line treatment in adult patients with chronic (>3 months) low back pain  
(facet joint pain or sacroiliac joint pain) who had a positive response to diagnostic block  
ICD-10 code: M54.5 low back pain 
MeSH terms: low back pain, zygapophyseal joint, sacroiliac joint 
Patients with acute trauma, fracture, malignancy, and inflammatory disease were excluded. 
Intervention Radiofrequency (RF) denervation (synonyms: radiofrequency neurotomy, 
radiofrequency ablation) 
No limits on the temperature were applied. Both continuous and pulsed RF were included. 
Control Placebo 
Other treatments* 
 
  
systematischer Review 
2016: Radiofrequenz-
denervierung bei 
chronischen Schmerzen 
im Bereich des 
Iliosakralgelenke sowie 
der lumbalen 
Facettengelenke  
Forschungsfrage 2016 
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Outcomes  
Efficacy  Pain 
 Functional status 
 Global improvement 
 Health-related quality of life 
 Ability to work 
 Satisfaction with treatment 
Safety  Complications 
Study design Randomised controlled trials 
* In deviation from the Cochrane review, studies comparing different methods of RFD were included for safety analysis only 
(but not for efficacy). 
 
In the 2016 report, the outcomes of pain, functional status, global improve-
ment and health-related quality of life, as well as complications, were defined 
as crucial to derive a recommendation. The remaining outcomes of patient 
satisfaction and ability to work were defined as important, but not crucial, to 
derive a recommendation. 
During the scoping process, a Cochrane Review [2] dealing with radiofre-
quency denervation for chronic back pain, which had a broader scope, includ-
ing pain from intervertebral discs and the dorsal root ganglion, was identi-
fied. Thus, the authors of the previous LBI-HTA assessment decided to use 
relevant parts of the Cochrane Review (dealing with facet and sacroiliac 
joints) as the primary source for the assessment. Additionally, a (systematic) 
search in Medline and PubMed using the search strategy from the Cochrane 
review (complemented by the search term “sacroiliac joint”) was conducted, 
and a hand search in PubMed performed. 
 
 
Results 
Clinical effectiveness 
10 randomised controlled trials evaluating radiofrequency denervation for 
facet joint pain were included. 6 studies compared the intervention with pla-
cebo (sham treatment), while the remaining 4 trials used steroid injections 
as comparator. 
For evaluating radiofrequency denervation for sacroiliac joint pain, 2 random-
ised controlled trials fulfilled the inclusion criteria. Both RCTs compared 
the intervention with placebo (sham treatment). 
The strength of evidence for the effectiveness of radiofrequency denervation 
for facet joint pain compared to placebo was considered low in reducing pain 
in the short term (≤ 1 month) and in increasing the global improvement in 
the intermediate term (1-6 months). Furthermore, the assessment revealed 
that RFD might not increase the functional status in the intermediate term, 
but might lead to an improvement between 6-12 months. Additionally, RFD 
might improve the quality of life at 3 months. These results were supported 
by a low level of evidence. 
insgesamt  
7 Endpunkte  
ausgewählt 
basierend auf  
Cochrane Review 
klinische Wirksamkeit: 
10 RCTs für 
Facettengelenke;  
2 RCTs für 
Iliosakralgelenke 
Evidenzstärke für RFD 
bei Facettengelenks-
schmerz niedrig bis  
sehr niedrig 
Summary of 2016 assessment 
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In comparison to steroid injections, the strength of evidence was low that 
RFD might reduce pain up to 12 months. A very low level of evidence sup-
ported the findings that RFD might neither improve the functional status 
between 6-12 months nor the quality of life up to 12 months. No evidence 
was available for the outcome of global improvement. 
In terms of sacroiliac joint pain, the strength of evidence for the effective-
ness of radiofrequency denervation in comparison to placebo (sham interven-
tion) was considered low to very low. RFD might not reduce pain or improve 
the functional status in the short term (≤ 1 month), but up to 3 months there-
after. However, the intervention might lead to a global improvement up to 3 
months. Furthermore, RFD might not increase the quality of life in the short 
term, but up to 3 months after the intervention. No evidence was available 
for any of the critical outcomes for observation periods longer than 3 months. 
 
Safety 
In addition to the 10 studies already included in the clinical effectiveness as-
sessment evaluating radiofrequency denervation for facet joint pain, 3 fur-
ther RCTs comparing different RFD methods were included for safety con-
siderations. There was very low evidence that RFD compared to placebo 
might not increase complications. In comparison to steroid injections, RFD 
does not lead to complications, but might cause superficial burns after the 
intervention and an initial increase in back pain. 
Regarding the safety assessment of radiofrequency denervation for sacroiliac 
joint pain, the two aforementioned RCTs were included. There was very low 
evidence that RFD compared to placebo might not increase serious compli-
cations. 
For both indications, the quality of evidence was downgraded due to impre-
cise data, study limitations, and inconsistent results across the studies.  
 
 
Recommendation 
The available evidence included in the 2016 report was not sufficient to prove 
that the assessed technology of radiofrequency denervation in adult patients 
with chronic (>3 months, facet joint- or sacroiliac joint) low back pain who 
had a positive response to diagnostic block is more effective than, and as safe 
as, the comparator(s) (placebo/sham intervention or conventional treatment). 
Therefore, the inclusion in the catalogue of benefits was not recommended, 
but a re-evaluation in 2019 was suggested.  
 
Evidenzstärke  
bei Schmerzen der 
Iliosakralgelenke niedrig 
bis sehr niedrig 
Sicherheit:  
13 RCTs für 
Facettengelenke;  
2 RCTs für 
Iliosakralgelenke 
Evidenzstärke  
sehr niedrig 
Aufnahme 2016  
nicht empfohlen  
aber Re-evaluation 
vorgeschlagen 
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UPDATE 2019 
1 Scope 
Although a re-evaluation of RFD should be performed, the scope of the pre-
sent assessment is different from the previous report from 2016. As commis-
sioned by the Austrian Ministry of Health, the present assessment should 
include a re-evaluation of RFD for the treatment of lumbar facet joint pain 
and an evaluation of RFD for the treatment of cervical facet joint pain, which 
was not part of the 2016 report. Furthermore, the efficacy and safety of RFD 
for the treatment of facet joint pain in patients suffering from osteoporosis 
should be evaluated. The use of RFD for sacroiliac joint pain was not fur-
ther considered. Therefore, the research question of the present assessment 
is defined as follows: 
 
 
1.1 PICO question 
Is radiofrequency denervation of the cervical and lumbar facet joints, in com-
parison to placebo or other non-surgical treatments in patients with or with-
out osteoporosis with chronic facet joint pain, more effective and safe concern-
ing pain, functional status, global improvement, health-related quality of life, 
ability to work, and satisfaction with the treatment and complications? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Second-line treatment in adult patients with or without moderate to severe osteoporosis 
with chronic (>3 months) low back pain (lumbar facet joint pain) or neck pain (cervical 
facet joint pain) who had a positive response to a diagnostic block 
ICD-10 code: M54.5 low back pain, M54.2 cervical neuralgia 
MeSH terms: low back pain, neck pain, zygophophyseal joint, post-menopausal or  
age-related/senile osteoporosis 
Patients with acute trauma, fracture, maligancy and inflammatory disease were excluded. 
Intervention Radiofrequency (RF) denervation 
(synonyms: RF neurotomy, RF ablation) 
No limits on the temperature were applied. Both continous and pulsed RF were included. 
MeSH terms: denervation (includes radiofrequency neurotomy), RF ablation 
Control Placebo/sham procedures RFD 
Other non-surgical treatments: epidural injections of local anasthetic or steroids 
 
Scope 2019:  
RFD bei Schmerzen im 
Bereich der zervikalen 
und lumbalen 
Facettengelenke sowie 
bei PatientInnen mit 
Osteoporose 
PICO-Frage 
Einschlusskriterien  
für relevante Studien 
Radiofrequency denervation for lumbar and cervical facet joint pain 
22 LBI-HTA | 2019 
Outcomes  
Efficacy  Pain 
 Functional status 
 Global improvement 
 HRQoL 
 Ability to work 
 Satisfaction with the treatment 
Safety  Procedure-related complications 
 Adverse events 
Study design  
Efficacy Randomised controlled trials 
Non-randomised controlled trials  
Safety Randomised controlled trials 
Non-randomised controlled trials 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is radiofrequency denervation? 
B0002 What is the claimed benefit of radiofrequency denervation in relation to the comparators? 
B0004 Who administers radiofrequency denervation and in what context and level of care  
is it provided? 
B0008 What kind of special premises are needed to use radiofrequency denervation? 
B0009 What supplies are needed to use radiofrequency denervation? 
A0020 For which indications has radiofrequency denervation received marketing authorisation or  
CE marking? 
A0021 What is the reimbursement status of radiofrequency denervation? 
 
Health problem and current use 
Element ID Research question 
A0001 For which health conditions and for what purposes is radiofrequency denervation used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for chronic low back pain or chronic neck pain? 
A0004 What is the natural course of chronic back pain or chronic neck pain? 
A0005 What is the burden of disease for patients with chronic low back pain or chronic neck pain? 
A0006 What are the consequences of chronic low back pain or chronic neck pain for the society? 
A0024 How is chronic low back pain or chronic neck pain currently diagnosed according  
to published guidelines and in practice? 
A0025 How is chronic low back pain or chronic neck pain currently managed according  
to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is radiofrequency denervation of the cervical and lumbar facet joints utilised? 
 
Clinical effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of radiofrequency denervation on mortality? 
D0005 How does radiofrequency denervation affect symptoms and findings (severity, frequency)  
of chronic low back pain or chronic neck pain? 
D0006 How does radiofrequency denervation affect progression (or recurrence) of chronic  
low back pain or chronic neck pain? 
D0016 How does the use of radiofrequency denervation affect activities of daily living? 
D0012 What is the effect of radiofrequency denervation on generic health-related quality of life? 
D0013 What is the effect of radiofrequency denervation on disease-specific quality of life? 
D0017 Was the use of radiofrequency denervation worthwhile? 
 
Radiofrequency denervation for lumbar and cervical facet joint pain 
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Safety 
Element ID Research question 
C0008 How safe is radiofrequency denervation in comparison to placebo or steroid injections? 
C0002 Are there harms related to dosage or frequency of applying radiofrequency denervation? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the  
use of radiofrequency denervation? 
C0007 Are radiofrequency denervation, steroid injections, injections with local anaesthetic or 
placebo interventions associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology and health problem and current use 
 Publications and guidelines identified by hand search 
 Background information from publications identified in database 
search: see Section 2.3 
For the domains of clinical effectiveness and safety, a systematic literature 
search was conducted, as described in detail in the following chapter.  
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 20
th
 of December 2018 
in the following databases: 
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
After deduplication, a total of 569 citations were included. The specific search 
strategy employed can be found in the Appendix.  
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Tri-
als) was conducted on the 21
st
 of January 2019, resulting in 51 potential rele-
vant hits. 
Manufacturers from the most common products (Halyard, Pajunk, Stryker, 
Avanos Medical and Cosman) were contacted on the 12
th
 of December 2018. 
However, they did not respond to our e-mail.  
No further hand search was conducted. 
 
 
Informationen aus 
Handsuche und 
Literatursuche für 
Beschreibung des 
Gesundheitsproblems 
und der Technologie 
systematische 
Literatursuche in  
4 Datenbanken  
Suche nach  
laufenden Studien 
insgesamt  
569 Publikationen 
identifiziert 
Methods 
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2.4 Flow chart of study selection 
Overall, 569 hits were identified after deduplication. All records were screened 
by two independent researchers. 37 records were screened in full text and 8 
studies fulfilled the inclusion criteria. Of these, 2 studies for cervical facet 
joint pain and 6 studies for lumbar facet joint pain (published after June 2015, 
the literature search date of the first assessment, and which were not includ-
ed in the 2016 assessment) were relevant for our assessment. No studies spe-
cifically including patients with osteoporosis were identified. The selection 
process is displayed in Figure 2-1. 
 
* for effectiveness: n=7 (lumbar facet joint pain: 5; cervical facet joint pain: 2); for safety: additional 1 RCT for lumbar facet joint pain 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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 Additional records identified 
through other sources  
(n=0) 
Records after duplicates  
removed 
(n=569) 
Records screened 
(n=569) 
Records excluded 
(n=532) 
Full-text articles  
assessed for eligibility 
(n=37) 
Full-text articles excluded,  
with reasons 
(n=29) 
 other study design (n=4) 
 Full text not available (n=8) 
 Erratum (n=2) 
 Background literature (n=15) 
 
Studies included in 
qualitative synthesis* 
(n=8) 
 RCTs (n=7) 
 NRCTs (n=1) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into a data extraction table by one researcher (EF) (see Ap-
pendix Table A-1, Table A-2, Table A-3, and Table A-4). Another researcher 
(SGG) checked the data for integrity and completeness. 
No further data processing (e.g., indirect comparison) was applied. The quali-
ty of the studies were systematically assessed using the revised Cochrane 
Risk of Bias tool (RoB 2.0) [3] for randomised controlled studies, and the 
Risk of Bias in non-randomised studies of intervention tool (ROBINS-I) [4] 
for non-randomised controlled trials (see Table A-5, Table A-6, and Table 
A-7 in the Appendix). 
 
 
2.6 Synthesis 
Based on the data extraction tables (see Appendix), data on each selected out-
come category were analysed across studies according to GRADE (Grading 
of Recommendations Assessment, Development and Evaluation) [5]. The re-
search questions were answered in plain text format with reference to GRADE 
evidence tables that are included in the Appendix, the results of which were 
summarised in Table 7-1 and Table 7-2. 
 
 
Daten der einzelnen 
Studien extrahiert und 
kontrolliert 
Bewertung des 
Biasrisikos mittels  
RoB 2.0 und ROBINS-I 
Bewertung der Evidenz 
sowie Beantwortung der 
Forschungsfrage mittels 
GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is radiofrequency denervation?  
The use of radiofrequency denervation (RFD) for the treatment of back pain 
was first described in the literature in 1975 [6]. Radiofrequency denervation 
is a minimally invasive procedure usually performed with local anaesthetic 
and mild sedation. During this outpatient procedure, the patient is positioned 
face down and the skin is anaesthetised with a local anaesthetic such as lido-
caine [7]. Before the RFD procedure is done, a (lateral branch or medial 
branch) nerve block is performed in order to verify that the pain is being 
transmitted by those nerves [8].  
RFD is done with the following elements: a radiofrequency generator, cannu-
las with active tips, and a thermocoupler that serves to sense the body tem-
perature and transmit the radiofrequency energy [6]. 
A radiofrequency generator produces an alternating electrical current with a 
frequency of 250 to 500 kHz through an insulated needle. At the tip of the 
needle, the electric field induces ionic movements in the tissue directly sur-
rounding the tip. The heat from the tip of the device is used to produce a small 
lesion in the nerves suspected of contributing to the pain. The heat causes 
ionic agitation and friction, resulting in protein denaturating, cellular mem-
brane disruptions, increased membrane permeability, and, finally, tissue ne-
crosis or lysis. The technique aims to interrupt the pain signals to the brain 
in order to eliminate the pain [6, 9, 10]. 
RFD procedures can be classified in low-intensity RFD (which is adminis-
tered constantly for 60-90 seconds at a specific temperature), cooled RFD 
(which involves the use of a cannula needle that has saline running through 
it to cool the tip), and pulsed RFD (which is done with signal interruption 
every half second, creating temperatures of 42° C) [6].  
Comparators include therapeutic intra-articular (steroid) injections or sham 
RFD. In the sham surgery, a radiofrequency needle is inserted into the same 
location as in RFD, but the electric current is not turned on [7]. 
Synonyms for radiofrequency denervation are the terms radiofrequency ab-
lation and radiofrequency neurotomy.  
B0002 – What is the claimed benefit of radiofrequency denervation  
in relation to the comparators? 
When the joint is determined to be the source of pain, as indicated by radi-
ograhic findings and supported by a positive diagnostic nerve block, pro-
longed pain relief may be achieved by RFD with destruction of the nerves to 
the affected joint. The procedure does not cure the source of pain, but de-
stroys the pain signal to the brain by damaging the nerve, which can result 
in pain relief lasting from 6 months to, occasionally, greater than 12 months 
[7]. After this period of time, however, the nerve will regenerate and the pain 
may return [8]. 
 
RFD ist  
minimal-invasive 
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Administration, investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers radiofrequency denervation and  
in what context and level of care is it provided?  
B0008 – What kind of special premises are needed to use radiofrequency 
denervation?  
B0009 – What supplies are needed to use radiofrequency denervation? 
According to the information received by the submitting hospital, the inter-
vention is performed at specialised centres. 
The intervention is performed by an experienced operation team, including 
an experienced orthopaedist, an assistant physician, a nurse, an anaesthetist 
(in the case of sedoanalgesia), and a radiological assistant for intraoperative 
X-ray monitoring.  
An operating room with intraoperative X-ray monitoring is needed for the 
intervention.  
 
Regulatory & reimbursement status  
A0020 – For which indications has radiofrequency denervation  
received marketing authorisation or CE marking? 
RFD for back pain is a procedure and is therefore not subject to regulation 
by the Food and Drug Administration (FDA). However, the FDA regulates 
RFD devices; hence, there are various devices listed in the FDA 510(k) 
Premarket Notification database. Currently, 40 items are listed under the 
device classification name ‘Generator, Lesion, Radiofrequency’ (Classifica-
tion Product Code ‘GXD’) [11]. Within the past 5 years, the following gen-
erators received FDA clearance: 
 Polaris RF Ablation System  
(Baylis Medical Company Inc.; approved 2019), 
 Intracept Intraosseous Nerve Ablation System  
(Relievant Medsystems; approved 2017) 
 MultigenTM 2 RF Generator System  
(Stryker Corporation; approved 2017) 
Since 2015, 8 RF lesion probe devices have been approved by the FDA 
(Classification Product Code ‘GXI’): 
 Intracept Intraosseuous Nerve Ablation System (Component  
Intracept RF Probe) (Relievent Medsystems; approved 2018) 
 Intracept Intraosseuous Nerve Ablation System Probe  
(Relievant Medsystems; approved 2017) 
 OWL RF Insulated Cannulae (Probe)  
(Diros Technology, Inc.; approved 2017) 
 Coolief* Cooled RF Probe (Halyard Health, Inc.; approved 2017) 
 Coolief* Cooled Radiofrequency Kit  
(Halyard Health, Inc.; approved 2016) 
 LCCS Disponsable RF Electrode, LCCS Reusable RF Electrode 
(LCCS Products Limited; approved 2016) 
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 Intracept Flexible Bi-Polar RF Probe and Easy Access Instrument Set 
(Relievant Medsystems; approved 2016) 
 Diros OWL Sterile Single Use TridentTM RF Insulated Cannulae, 
Models DTR and DTRH (Diros Technology, Inc.; approved 2015) 
The probes are used in conjunction with an RF generator to create RF le-
sions in nerves. All components have received FDA clearance as substantial-
ly equivalent to an approved predicate device. 
Of the above list, the RF Puncture Generator (Baylis Medical Company Inc.) 
and the Coolief* Cooled Radiofrequency Kit (Halyard Health, Inc.), as well 
as the LCCS Disponsable RF Electrode and the LCCS Reusable RF Elec-
trode (both manufactured by LCCS Products limited), also received CE mark-
ing [12-14]. However, we were not able to identify a comprehensive list of 
other current CE-marked RFD systems. 
A0021 – What is the reimbursement status  
of radiofrequency denervation? 
Currently, radiofrequency denervation of the facet joints can be reimbursed 
via the Austrian DRG system (Leistungsorientierte Krankenanstaltenfinan-
zierung/LKF) using the code AJ140 ‘percutaneous destruction of peripheral 
nerves’. 
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4 Health problem and current use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is radiofrequency ablation/denervation used? 
Radiofrequency ablation is one of several types of ablation therapy. There-
fore, it can be used to treat a wide range of conditions. For example, RFA is 
sometimes used in oncology [15] to treat (bone, kidney, liver, lung or pros-
tate) cancers including bone metastases [16] or precancerous lesions in the 
esophagus (Barrett’s esophagus), in cardiology [17] to treat arrhythmias 
(e.g., supraventricular tachyarrhythmias), or in dermatology [18] to treat 
skin lesions. Finally, RFA is used in pain therapy, e.g., for the treatment of 
neck or low back pain (LBP). 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
In the scope of this assessment, chronic low back pain deriving from the lum-
bar facet joints and chronic neck pain deriving from the cervical facet joints 
are the conditions of interest. Low back pain is defined as pain and discom-
fort, localised between the costal margin and above the inferior gluteal folds, 
with or without referred leg pain, that persists for at least 12 weeks (Europe-
an Guidelines from 2004 [19]). Accordingly, neck pain is defined as pain lo-
cated in the anatomical region of the neck with or without radiation to the 
head (cervicogenic headache), trunk and upper limbs [20]. 
Supplementary to the previous assessment, patients suffering from facet joint 
syndrome due to osteoporosis will be considered. According to the informa-
tion from the submitting hospital, the intervention for this particular sub-
group might be more beneficial than a surgical treatment via spondylodesis 
(spinal fusion). 
A0003 – What are the known risk factors of chronic back pain  
or chronic neck pain? 
There are many possible causes for low back pain, e.g., infections, tumours, 
fractures, or spinal disc herniation. The majority of patients (approximately 
85%) seen in the primary care, however, have non-specific low back pain, 
which is not attributable to a recognisable, known specific pathology or ana-
tomical structure (e.g., infection, tumour, fracture) [10, 21]. Suspected sources 
of back pain include lumbar facet (zygapophyseal) joints, sacroiliac joints, 
and degenerated intervertebral discs [10]. 
Risk factors associated with back pain include smoking, obesity, age, female 
gender, physically strenuous work, sedentary work, psychologically strenuous 
work, low educational attainment, job dissatisfaction, and psychological fac-
tors such as somatisation disorder, anxiety, and depression [21].  
Furthermore, osteoporosis has been identified as a major risk factor. The 
disease is characterised by low bone mass, microarchitectureal disruptions, 
as well as an overall skeletal fragility. The only clinical manifestations (of the 
otherwise asymptomatic condition) are fractures, whereas vertebral fractures 
and those of the hip and the femur occur most frequently [22]. If the verte-
bral bodies of the spine are affected, the fractures could result in a signifi-
cant amount of back pain [23].  
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Among the most common causes for neck pain (cervicalgia) are degenerative 
changes of the lower cervical spine (from C3 to C7) [24]. In addition, the 
symptom can arise from diverse musculoskeletal conditions (e.g., spondylo-
sis), neurologic diseases (cervical radiculopathy) or non-spinal disorders like 
infections or malignancies [25]. 
Several risk factors strongly associated with a first episode of neck pain, like 
depressed mood, high role conflict or perceived muscular tension, have been 
identified. Furthermore, awkward and/or sustained postures in work were 
most commonly reported [26]. More general risk factors include age, gender, 
history of neck pain, occurrence of other musculoskeletal problems, repeti-
tive strain and poor self-rated health [27] [28]. 
A0004 What is the natural course of chronic back pain  
or chronic neck pain? 
Chronic low back pain is seen as recurring or persistent condition showing a 
fluctuating course over time. It is likely that patients who report LBP will 
continue to report LBP in the future [29]. After an initial episode of low back 
pain, 44-78% of the patients suffer relapses of pain [19]. 
Neck pain often starts asymptomatically. Evidence of age-related chronic de-
generation of the vertebral disc (spondylosis) is found in 25% of adults un-
der 40 years of age, in 50% of adults over 40 years of age, and in 85% of 
adults over 60 years of age [30]. Generally, the progression is highly variable. 
Usually, half of the patients experience a benign form in which the episodes 
of neck pain resolve within one year [27]. About 50% to 80% report the recur-
rence of neck pain 1 to 5 years later, and approximately 30% develop chronic 
syndromes [31, 32]. Among the factors known to contribute to an accelera-
tion of the symptom are a congenitally narrow vertebral canal, exposure to 
significant trauma, certain physical activities like soccer or rugby, and hav-
ing dystonic cerebral palsy including the cervical muscles [30].  
 
Effects of the disease or health condition on the  
individual and society 
A0005 – What is the burden of disease for patients  
with chronic back pain or chronic neck pain? 
Chronic low back pain is one of the most commonly reported pain condi-
tions. It is often characterised by a long duration of the illness and multiple 
recurrent episodes of pain. Patients with low back pain often report comor-
bidities such as osteoarthritis, cardiovascular and cerebrovascular diseases, 
as well as mental disorders such as depression, anxiety disorders, and post-
traumatic stress disorder. International data also show a positive correlation 
between low back pain and symptoms such as migraine and headache, ex-
haustion, and respiratory symptoms [33]. 
In 2015, low back and neck pain ranked as the fourth leading cause of disa-
bility-adjusted life years (DALYs) globally [34]. Approximately half of all in-
dividuals will experience a clinically important episode of neck pain over the 
course of their lifetime, whereby more women than men are affected (5.77% 
vs. 3.89%), with the highest prevalence in the age group of 40-45 years [35]. 
More than 330 million people (4.82% of the global population) are affected 
by episodes of neck pain lasting more than 3 months [34]. 
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A0006 – What are the consequences of chronic back pain  
or chronic neck pain for the society? 
Low back pain is one of the most expensive diseases in industrialised coun-
tries. It is one of the most frequent causes for inability to work and early re-
tirement. In Germany, low back pain is estimated to cause direct costs of 
€ 8.4 billion per year. According to international estimates, 85% of these costs 
are due to productivity losses because of inability to work and the remaining 
15% are spent on medical treatment [33]. In the United States, costs of low 
back pain have been estimated to be more than 100 billion USD per year, 
primarily due to lost productivity [9]. 
Similarly, the economic burden of neck pain is high, including the cost of 
treatments, lost wages and compensation expenditures. It is second only to 
low back pain in workers’ compensation claims in the US and accounts for 
18% of all disability payments in Sweden [32]. 
Both conditions are among the most common medical conditions requiring 
medical care and affecting an individual’s ability to work and manage the 
daily activities. In the US, the medical costs for all back-related conditions 
were $253 billion in 2013 (without chiropractic care, physical therapy, mas-
sage or other types of alternative care, and exclusive outpatient treatment 
costs [36]. 
 
Current clinical management of the disease or health condition 
A0024 – How is chronic back pain or chronic neck pain  
currently diagnosed according to published guidelines and in practice? 
Chronic low back pain is diagnosed by a detailed medical history (anamne-
sis). The medical history should include asking for the onset of symptoms, 
duration, localisation and causes of pain, correlation of pain with specific po-
sitions and movements, earlier pain episodes, problems in activities of daily 
living, as well as psychosocial risk factors. An important part of the medical 
history is asking for red flag symptoms, which can indicate specific causes 
(e.g., fracture, tumour, infection, radiculopathy/neuropathy) with potentially 
urgent need for action [33, 37]. 
An additional physical examination (e.g., inspection, palpation, test of the 
mobility of the lumbar spine, examination of the sacroiliac joint) [33, 37] aims 
at distinguishing between non-specific vs. specific (physical or mental) caus-
es (as the aforementioned red flag symptoms do). Medical imaging also aims 
at identifying specific causes for low back pain. However, study results ques-
tion its use as a single diagnostic modality, because degenerative changes 
(here: osteoarthritis of facet joints detected by CT) are common in the gen-
eral population and increasing with age [38]. A large population-based study 
failed to find an association of this CT-verified presence of degenerative os-
teoarthritis and low back pain [38]. 
During the care process, the assessment of psychosocial and somatic risk fac-
tors for pain chronification (‘yellow flags’; e.g., depressiveness, pain-related 
cognition, passive pain behaviour, workplace-related factors, iatrogenic fac-
tors) is recommended [33]. 
Due to the vast amount of differential diagnosis, the initial assessment of neck 
pain focuses on largely excluding serious condition ‘red flags’, including re-
cent major trauma, underlying infections or cancer [25]. In patients without 
‘red flags’ the evaluation consists of a detailed history and a physical examina-
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tion (including observation, determination of the range of motions and mus-
cle palpation), a neurologic assessment (including muscle strength, sensory, 
reflex and gait testing, as well as an evaluation for upper motor neuron signs), 
and an assessment of radicular symptoms or signs using provocative manoeu-
vres (Spurling’s maneuver, Elvey’s upper limb tension test, or manual neck 
distraction test). Finally, the severity of pain should be assessed [25]. 
A0025 – How is chronic back pain or chronic neck pain  
currently managed according to published guidelines and in practice? 
Conservative treatment options for chronic low back pain may include drug 
therapies with non-steroidal antirheumatics/antiphlogistics (NSARs), and, if 
applicable, opioid analgesics, muscle relaxants or anti-depressants [33]. In 
addition, several non-drug therapies are recommended (physical activity and 
movement therapy, therapeutic exercise, patient education [information/train-
ing], ergonomics, multimodal, multi-, and interdisciplinary treatment/reha-
bilitation, self-management programmes, occupational therapy, behavioural 
therapy, or progressive muscle relaxation). 
According to this guideline, invasive therapeutic procedures are not recom-
mended for the treatment of patients with non-specific low back pain [33], 
due to the lack of reliable data (despite numerous studies) for percutaneous 
procedures, and the lack of studies on the use of surgical procedures. 
The Austrian Guideline for the management of acute and chronic non-specific 
low back pain, published in 2018 [37] recommends multidisciplinary treat-
ment programmes for chronic low back pain. Single interventions, such as 
pharmacological treatment only, are not considered to be sufficient for alle-
viating pain in the long term, as well as to prevent disability and work absenc-
es [37].  
Due to the diversity and complexity of possible underlying conditions, the 
treatment of neck pain has to be individualised and adjusted according to pain 
control and length of symptoms. Initially, posture modifications are recom-
mended (e.g., adjustment of sleep positions and avoidance of sustained seat-
ed posture).  
In the case of persistent pain, physical therapy, spinal manipulation and 
manual therapy are recommended [39]. Furthermore, pharmacological treat-
ments with acetaminophen or non-steroidal antirheumatics/antiphlogistics 
(NSARs) might be effective for patients who suffer from mild to moderate 
pain episodes. Patients experiencing severe pain might find relief when us-
ing opioid analgesics or tramadol. Additionally, muscle relaxants could be 
useful [39].  
 
Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment is adult patients with chronic (long-
er than three months) low back pain or neck pain, who had a positive response 
to a diagnostic block in the facet joints. Furthermore, patients with facet joint 
syndrome due to osteoporosis were considered. In contrast, patients with fac-
et joint pain due to acute trauma, fractures, malignancies or inflammatory 
diseases were excluded.  
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A0023 – How many people belong to the target population?  
According to a health survey conducted by Statistik Austria in 2014, 23% of 
Austrian men and 26% of Austrian women were affected by chronic low back 
pain or other chronic back problems in the previous 12 months. The preva-
lence increases with age, and more women are affected than men [40]. The 
lifetime prevalence of low back pain (in total) is estimated to be up to 84% 
[19].  
In total, 1.34 million (19%) of the Austrian employees suffer from chronic 
neck pain. The prevalence is higher in women than in men (23% vs. 14%) 
and increases with age [41]. 
Prevalence estimates of facet joint pain are provided by the RFD studies’ au-
thors as follows: Facet-joint pain accounts for 15% to 50% [42-44] of low 
back pain. Against the backdrop of the high prevalence of degenerative chang-
es detected in facet joints (63% in a sample of 188 men and women, at mean 
~52 years old [38]) of the general population, the provided (high) propor-
tion of ‘facet joint pain’ as a cause of low back pain can be questioned. Due to 
non-specific imaging and clinical testing, reliable epidemiological data seems 
to be missing.  
The prevalence of individuals with osteoporosis among the adult population 
in Austria older than 50 years is estimated to be 5.5% (460,000 individuals), 
of which 80.4% are female [45]; however, no information about how many of 
them are suffering from facet joint syndrome is available. 
A0011 – How much is radiofrequency denervation  
of the facet joints utilised? 
According to the information provided by one Austrian hospital, the annual 
frequency in this hospital is estimated to be 80 procedures of radiofrequency 
denervation. In 2017, 70 treatments were recorded in the submitting hospi-
tal. The number of facet joint radiofrequency denervation procedures in Aus-
trian hospitals is estimated with 800 per year. 
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5 Clinical effectiveness 
5.1  Outcomes 
For both conditions (chronic neck pain and chronic low back pain),  
the following outcomes were defined as crucial to derive a recommendation: 
 Pain 
 Functional status 
 Global improvement 
 Health-related quality of life 
Changes in pain intensity were measured in 4 studies [46-49] using the Vis-
ual Analogue Scale (VAS), which is a continuous scale usually ranging from 
0 to 100 mm in length; ranges from 0-4 mm indicate ‘no pain’ while 75-100 
mm indicate severe pain [50]. The clinically minimum important difference 
(CIMD) varies according to the severity of pain reported, and ranges between 
10-14 mm [51]. Two studies [52, 53] applied the Numeric Rating Scale (NRS-
11), which represents an 11-item, segmented version of the VAS.  
One study [54] determined the absolute number of days with intense cervi-
cogenic headache (resulting from neck pain with cervical facet joints involve-
ment), and reported those patients who experienced a reduction of at least 
30 days between baseline and indicated time point. In addition, the authors 
performed algometry measurements (pain pressure threshold measured with 
an algometer). The difference in the pain threshold between the non-symp-
tomatic and the symptomatic side was calculated and the average of three 
single trials (performed within a few minutes) was used. The CIMD for pa-
tients with neck pain has been determined as 0.07 kg/f (right) and 0.48 kg/f 
(left), if measured between the C5/C6 segment [55]. 
The functional status of the low back was ascertained in 3 studies [47, 49, 
52] using the Oswestry Disability Index (ODI). First published in 1980, the 
current version dates from 2000 [56]. The self-completed questionnaire con-
tains 10 topics, each of which is scored on scale from 0 to 5, with 0 indicating 
‘least amount of disability’ and 5 indicating ‘most severe disability’. The scores 
of all questions are summed, multiplied by two, and given in percentages 
(0%-100%). Finally, the results are summarised into five broad categories 
ranging from minimal disability (0%-20%) to bed-bound or exaggeration of 
the symptoms (81%-100%). A difference between 10 points or 30% of the 
score is assumed to correspond to the CIMD [57]. 
One study [48] applied the Schober index, which is a clinical measure of flex-
ion of the lumbar spine. During the physical examination, the patients were 
advised to maintain an erect position. The bilateral iliac crests were labelled 
at 10 cm above and 5 cm below the site where the back midline crossed. The 
patients were then asked to bend forward as much as possible to measure the 
increase in distance between the two markers. The evaluations were per-
formed by independent observers. A change of 1 cm is considered as CIMD 
[58]. 
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The functional status of the neck was measured by applying certain range of 
motion (active movements) tests with a baseline inclinometer in three dimen-
sions (maximal flexion/extension, lateral flexion, and rotation). For all move-
ments, the average of three measurements was calculated. The CIMDs are 
given as follows: flexion: 6.0°, extension: 4.0°, rotation right: 10.0°, rotation 
left: 5.0°, lateral flexion right: 3.0°, and lateral flexion left: 5.0° [55]. 
Different tools were used to study the non-specific outcome measure of global 
improvement. Five studies [46, 47, 52-54] determined the Global Perceived 
Effect (GPE) by asking patients to rate, numerically, how much their condi-
tion has improved or deteriorated from the predefined time point, either a 4-
point scale (complete relief of pain, more than 50% relief, no effect, increase 
in pain) [47] or a 7-point scale from either 1-7 (fully recovered to worse than 
ever) [52] or from -3 (much worse) to +3 (much better) [46] was used. The 
CMID on the 7-point scale is considered to be 1.26 points (18% difference) 
[59]. 
A single study [48] applied the Surgical Efficacy Criteria of the Spine Sur-
gery Group of the Orthopedic Branch of Chinese Medical Association, which 
is divided into four categories: excellent (the patient’s pain disappeared, the 
lumbar range of motion was restored, and the patient returned to normal 
life), good (the patient’s pain was eliminated, the lumbar range of motion was 
partly restored, and the patient returned to normal work and life), eligible 
(the patient’s pain was partly relieved, the lumbar range of motion was partly 
restored, and the patient was unable to return to normal work and life), and 
poor (treatment had no effect or the symptoms were aggravated and the re-
lated signs did not improve). 
Health-related quality of life was assessed by calculating the mean health 
scores comprising the generic 36-item questionnaire compiled from the Rand 
Health Insurance Long Form Health Status Scale (RAND-36), the West Ha-
ven-Yale Multidimensional Pain Inventory (MPI) in the Dutch language 
(MPI-DLV) and the Dutch version of the Symptom Checklist-90 (SCL-90) 
[46] or by using the EQ-5D-3L [52]. 
The Rand Health Insurance Long Form Health Status Scale (RAND-36) in-
vestigates the HRQoL in the dimensions of physical function, social function, 
role physical limitations, role emotional limitations, mental health, vitality, 
bodily pain, and general health. The answers are then transformed into a 0-
100 scale, whereby a higher score is indicative of less disability. The CMID 
is considered to be 4 arbitrary units [60]. The West Haven-Yale MPI assesses 
the adaptation to chronic pain and is composed of 52 items. The outcome is 
given on a 7-point scale [61]. (No information regarding the CMID was found.) 
The SCL-90 consists of 90 items investigating 9 primary symptom dimen-
sions (e.g., somatisation, depression, interpersonal sensitivity) and 3 global 
distress parameters. (No information about the CMID was found.) The EQ-
5D-3L is a standardized instrument for measuring the generic health status. 
It is composed of 5 dimensions (mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression). The respondents rate their level of severity 
on a 3-level scale. The CMID is considered to be 0.10 arbitrary units [62]. 
The outcomes of 
 Patient satisfaction and  
 Ability to work 
were defined as important, but not crucial, to derive a recommendation. 
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5.2 Included studies 
Cervical facet joint pain: study and patient characteristics 
Two randomised controlled studies [46, 54] were included for evaluating RFD 
in patients with cervical facet joint pain. One study [54] compared the inter-
vention with a placebo/sham treatment, while the other study [46] used in-
jections with local anaesthetics as a comparator. 
These studies were conducted in the Netherlands [46] and in Norway [54]. 
Neither of the two studies, which were published in 2004 [54] and 2006 [46], 
provided information about potential funding sources. The sample sizes were 
12 and 30 patients, with an equal amount of individuals (n=21) in the inter-
vention and control groups.  
Both trials used the criteria of Sjaastad for diagnosing cervicogenic headache. 
In the placebo-controlled trial, the patients had to suffer from cervicogenic 
headache for more than 1 year. Furthermore, the participants had to have ex-
perienced an insufficient effect of appropriate prophylactic headache medi-
cation. Additionally, any cerebral CT or MRI or cervical MRI had to be with-
out significant pathology [54]. In the steroid injection study, the headache 
had to be persistent for more than 2 years, including significant pain periods 
(VAS score of more than 50 mm) of at least 2 days a week [46].  
The mean age of patients ranged between 45 and 53 years. In both studies, 
patients in the control group were slightly older (1.6 years and 8.0 years, re-
spectively). The percentage of females was 73% [46] and 50% [54]. The fol-
low-up periods were 12 months [46] and 24 months [54], respectively.  
Loss to follow-up ranged from 8.3% [54] to 30% [46]. 
The study characteristics and the results of the included studies are displayed 
in Table A-1. 
 
Cervical facet joint pain: quality assessment 
The study of Stovner et al. [54] has been judged as having a low risk of bias. 
In contrast, the study of Haspeslagh [46] was evaluated to have a high risk of 
bias due to potential deviations from intended interventions and due to miss-
ing outcome data. 
The results of the quality assessment of the included studies are displayed in 
Table A-5 and in the evidence profile in Table A-8. 
 
Lumbar facet joint pain: study and patient characteristics 
In the course of the literature search for this update, 5 studies investigating 
the effect of radiofrequency denervation for lumbar facet joint pain, and 
which have been published since the first assessment in 2016, were identi-
fied. 4 of these were randomised controlled trials [47, 48, 52, 53], while 1 study 
was designed as a non-randomised controlled study [49]. 2 studies [47, 53] 
used a sham procedure as a comparator; 2 studies compared the intervention 
with a steroid injection [48, 49]. In one clinical trial, RFD in combination 
with a standardised exercise programme was compared to the standard exer-
cise programme alone [52]. 
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2 trials were conducted in the Netherlands, and the remaining 3 studies in 
China, Egypt and Turkey. All of the studies were published between 2016 
and 2018. The sample sizes of the trials ranged from 60 to 120 participants, 
with a total number of 180 patients in the placebo-controlled studies, as well 
as in the steroid injection controlled studies. The only exception was the ex-
ercise-controlled trial with a total number of 251 patients. The total study 
population comprised 571 participants, of which 285 received RFD. 
Patients were included into the studies if the low back pain lasted for more 
than 3 months [49, 53], 6 months [48], or more than 12 months [47]. No def-
inition regarding the duration of the symptoms was given in 1 study [52]. In 
4 studies, the participants had to experience a failure of any previously re-
ceived conservative treatment [47, 49, 52, 53]. Only normal radiological find-
ings were accepted in the study of Yasar et al. [49], while radiographic find-
ings indicating deviations from asymptomatic statement were tolerated by 
Zhou and colleagues [48]. Furthermore, the studies differed as either 1 posi-
tive diagnostic block [48, 49, 52, 53] or 2 diagnostic blocks (on different occa-
sions) [47] had to be performed to localise the cause of the pain. The reduc-
tion of pain after the block had to reach 50% [52] to 80% [48], near complete 
pain reduction [47], or at least 2 points on the NRS. No information regard-
ing the amount of reduction after the diagnostic block was given in 1 trial [49]. 
The mean age of patients ranged from 55 to 65 years in 4 trials. A single study 
investigated younger patients (43 to 47 years) [49]. The percentage of female 
participants was above 50% in 3 studies [47, 52, 53]. In the remaining 2 (ster-
oid-injection) studies, the percentages of females were 45% [49] and 26% [48]. 
Patient follow-up ranged from 6 months to mostly 12 months; 1 study used a 
maximum observational period of 36 months [47]. 
Loss to follow-up ranged from 0% [47, 48, 53] to 29% [52]. 1 trial did not re-
port on drop-outs [49]. 
The study characteristics and the results of the included studies are displayed 
in Table A-2, Table A-3, and Table A-4. 
 
Lumbar facet joint pain: quality assessment 
One placebo-controlled trial [47] was judged to have a low risk of bias on a 
single study level, while the other placebo-controlled trial [53] was consid-
ered as having a high risk of bias due to the possibility of a crossover for the 
sham group after a minimum period of 3 months. The study investigating the 
effect of RFD in combination with a standard exercise programme [52] was 
assessed as having a high risk of bias due to the non-blinding of patients and 
caregivers, bias due to missing data, and putative bias in the measurement of 
the outcome due to the non-blinding of the patients (i.e., overestimation of 
effects due to self-reported outcomes of patients). 
The steroid injection studies were assessed as having a high risk of bias either 
due to potential confounding [49], or due to potential deviation from the in-
tended interventions, and in the measurement of the outcome [48].  
The results of the quality assessment of included studies are displayed in 
Table A-6 and Table A-7, and in the evidence profile in Table A-9. 
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Facet joint syndrome in patients with osteoporosis 
No studies investigating radiofrequency denervation in patients with facet 
joint syndrome due to osteoporosis were identified through the systematic 
literature search; neither did any of the included studies provide data on that 
particular topic. Therefore, results are only presented for lumbar and cervi-
cal facet joint pain. 
 
 
5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of radiofrequency 
denervation on mortality? 
Mortality is not a relevant outcome for assessing the clinical effectiveness of 
radiofrequency denervation, since neither the disease nor the intervention is 
life-threatening. Therefore, none of the included studies reported this out-
come. 
 
Morbidity (Pain) 
D0005 – How does radiofrequency denervation affect  
symptoms and findings (severity, frequency) of chronic neck pain  
or chronic low back pain? 
The 2 outcomes, pain intensity and global improvement, were available to 
answer this question. 
Cervical facet joint pain 
Improvement in pain intensity was reported in both studies [46, 54]:  
After 8 weeks, the percentage of patients reporting an improvement in pain 
intensity differed by 1.7% in favour of the intervention (43.9% vs. 42.4%). 
However, the result was not statistically significant (p=0.87) [46]. Addition-
al measurements were performed at 16 weeks (23.9% vs. 50.1%; p=0.17), 6 
months (28.5% vs. 49.4%; p=0.38) and at 12 months (16.8% vs. 49.9%; p= 
0.34), but since cross-over at 16 weeks to other therapies was optional, the 
data provided no further evidence. 
In the placebo-controlled trial, 66.7% of the patients (4 out of 6) in the inter-
vention group reported a reduction of at least 30 days with intense headache 
compared to 33.3% of the patients (2 out of 6) in the control group at 3 
months of follow-up. Between 12 and 24 months, fewer patients of the inter-
vention group experienced a reduction of intense headache days compared 
to patients of the control group (20% vs. 50%-60%) [54]. The statistical sig-
nificance of these results was not provided by the authors. 
Changes in the global improvement were reported in two studies [46, 54]: 
The outcome was assessed using the Global Perceived Effect (GPE) and/or 
successful VAS in one study [46]. At 8 weeks, 80% of the patients in the in-
tervention group and 66.7% of the patients in the control group reported a 
global improvement. In addition, the outcome was assessed at 16 weeks (66.7% 
vs. 53.3%) and 12 months (53.3% vs. 46.7%), but failed to show a statistically 
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significant effect. The second study [54] reported the outcome at 3 months 
(50% vs. 33.3%), 12 months (40% vs. 0%) and 24 months (60% vs. 16.7%). 
However, the statistically significance of the result was not reported. 
Lumbar facet joint pain 
Improvement in pain intensity was reported in all 5 studies [47-49, 52, 53]:  
Applying the NRS, one placebo-controlled trial [53] reported a similar reduc-
tion in pain intensity (MD: -1.9; p=0.66) in both groups 1 month after treat-
ment. (No detailed results for other time points were provided. However, the 
authors stated that no statistically significant differences between groups oc-
curred.) Comparing patients who received RFD with patients of the sham 
control group, the second study reported a VAS reduction of at least 50% 
throughout the entire follow-up period [47]: At 3 months, 75% of patients in 
the intervention group compared to 57.7% of patients in the control group in-
dicated a reduction in pain intensity. Further measurements were performed 
at 6 months (60% vs. 20%), 12 months (45% vs. 7.5%), 24 months (17.5% vs. 
2.5%) and 36 months (12.5% vs. 2.5%). (The statistical significance of the 
difference between the 2 groups was not provided by the authors.) 
In one steroid-injection controlled study [48], significantly lower VAS scores 
were reported in patients of the intervention group compared to patients of 
the control group (p<0.01). At 1 week, the mean VAS score in the interven-
tion group was 1.4 compared to 1.9 in the control group. At 1 month, the 
scores in the respective groups were 1.4 and 3.6. After 6 months, the mean 
VAS scores were 1.7 and 5.8, respectively. In the second steroid-injection tri-
al [49], the mean VAS scores in the intervention and control groups were 
measured at 3 months (2.5 vs. 3.3), 6 months (2.3 vs. 3.3), 9 months (2.7 vs. 
2.5) and 12 months (3.0 vs. 3.0). (The statistical significance of the difference 
between the 2 groups was not provided by the authors.) 
If RFD was used in combination with a standardised exercise programme 
[52], measurements of the pain intensity in both groups were performed at 3 
weeks (5.17 vs. 5.92, p=0.18), 6 weeks (5.19 vs. 5.92; p=0.02), 3 months (5.19 
vs. 5.90; p=0.55), 6 months (4.61 vs. 4.84; p=0.91), 9 months (4.66 vs. 4.73; 
p=0.53), and 12 months (4.49 vs. 4.44; p=0.13) by applying the NRS. No 
significant differences in the mean pain intensity scores between the inter-
vention and control groups were found throughout the follow-up period. 
Differences in the global improvement were extracted from 4 studies  
[47, 48, 52, 53]: 
In order to assess this outcome, the Surgical Efficacy Criteria of the Spine 
Surgery Group were applied in 1 injection-controlled trial [48]. At 6 months, 
62.5% of the patients receiving RFD and 12.5% of the patients in the respec-
tive control group were evaluated as experiencing an ‘excellent’ improvement. 
Accordingly, 27.5% vs. 30%, were rated as having made ‘good’ improvements, 
while 7.5% vs. 5.0% were categorized as experiencing ‘eligible’ improvements, 
compared to 2.5% vs. 52.5% who were rated as having a ‘poor’ global improve-
ment. The differences between the two groups were reported as statistically 
significant (p<0.01). 
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Three studies assessed the outcome applying the Global Perceived Effect scale 
(GPE). Van Tilburg and colleagues [53] reported a mean difference of -0.1 
and -0.2 between patients of the intervention group and patients of the con-
trol group at 1 and 2 months, respectively. The differences were not statisti-
cally significant. Moussa et al. [47] documented the percentage of patients 
reporting an improvement of more than 50%. The outcome was assessed at 
3 months (65% vs. 50.0%), 6 months (52.5% vs. 15%), 12 months (37.5% vs. 
2.5%), 24 months (10% vs. 2.5%), and 36 months (7.5% vs. 0%). However, 
the statistical significance of the difference between the 2 groups was not pro-
vided by the authors. In the third study [52], the outcome was given as num-
ber of patients improving by 1-2 scores and assessed at 3 weeks (RR=5.41; 
95% CI: 2.29-10.34; p>0.001), 6 weeks (RR=2.71; 95% CI: 1.37-4.68; p= 
0.005), 3 months (RR=1.35; 95% CI: 0.81-2.05; p=0.24), 6 months (RR=1.04; 
95% CI: 0.64-1.12; p=0.85), 9 months (RR=0.81; 95% CI: 0.48-0.57; p=0.35) 
and 12 months (RR=0.90; 95% CI: 0.55-1.33; p=0.65). Thus, a statistically 
significant difference in favour of the intervention was found between 3-6 
weeks post RFD.  
D0006 – How does radiofrequency denervation affect progression (or 
recurrence) of chronic neck pain or chronic low back pain? 
Cervical facet joint pain 
Long-term data on pain improvement was reported in 1 of 2 studies [54]: 
Follow-up data (24 months) was provided by 1 study comparing RFD with 
placebo in 12 patients [54]. No difference in the outcome (reduction of at least 
30 days of intense headache) was detected between 12 and 24 months; the 
percentage of participants reporting a reduction remained at 20% in the in-
tervention group compared to a percentage of 66.7% in the respective con-
trol group, suggesting no long-term effect of the treatment. 
Lumbar facet joint pain 
Long-term data on pain improvement was reported in 1 of 5 studies [47]: 
At 24 months, 17.5% of the patients treated with RFD reported a reduction 
in pain intensity of at least 50%, compared with 2.5% of patients in the pla-
cebo group. At 36 months, the percentages were 12.5% vs. 2.5%, respectively, 
suggesting that more participants benefit from intervention in the long term. 
(However, the statistical significance of the difference between the two groups 
was not provided by the authors.) 
 
Functional status & ability to work 
D0016 – How does the use of radiofrequency denervation  
affect activities of daily living? 
The two outcomes of functional status and ability to work were available to 
answer this question. 
Cervical facet joint pain 
Differences in the functional status were reported in 1 of 2 studies [54]: 
The placebo-controlled study determined changes from baseline to 3 differ-
ent time points after the intervention by several range of motion tests and by 
algometry. Regarding the neck flexion/extension at 3 months, 14% of the pa-
tients in the intervention group reported a change, compared to 20% of the 
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patients in the control group (p=0.9). At 12 months, 6% vs. 6% (p=not ap-
plicable) reported changes, and after 24 months, 14% vs. 8% (p=0.7) observed 
differences. Regarding the neck lateral flexion at 3 months, mean scores of 
10° vs. 4° (p=0.6) were reported. Additional measurements at 12 months (6° 
vs. 5°; p=0.6) and 24 months (-2° vs. 7°; p=0.6) were performed. Regarding 
the neck rotation movement, differences of 0° vs. 4° were observed 3 months 
after the intervention (p=not applicable). At 12 months, the respective values 
were 9° vs. -14° (p=0.3), and at 24 months the scores were reported as -8° vs. 
-6° (p=0.9). Changes in the algometry measurements were documented at 3 
months (-24 vs. -19; p=0.9), 12 months (-88 vs. -42; p=0.1), and 24 months 
(0 vs. -35; p=0.5). However, the differences were not statistically significant.  
None of the included RCTs for cervical facet joint pain reported the outcome 
‘ability to work’. 
Lumbar facet joint pain 
Changes in the functional status were reported in 4 of 5 studies [47-49, 52]: 
Differences in the functional status were reported by 1 placebo-controlled trial 
[47] using the ODI. The mean differences between the intervention and con-
trol groups were highest between 6 months and 12 months of follow-up (30 
and 35.7, respectively), while at 24 months the difference declined to 9.1. The 
smallest variations were observed at 3 months and 36 months post interven-
tion (4.5 and 5.3, respectively). (The statistical significance of the difference 
between the two groups was not provided by the authors.) 
In 1 steroid-controlled trial [48], significant differences between intervention 
and control group were found between 1 month (9.0 vs. 8.9; p<0.05) and 6 
months (8.8 vs. 6.2; p<0.01), indicating an increased flexibility of the lum-
bar spine in patients of the intervention group as measured with the Schober 
index. In the second trial [49], the functional status of the participants was 
measured using the ODI. At 3 months (18.9 vs. 24.1), 6 months (14.9 vs. 24.8), 
and 9 months (10.4 vs. 12.2), a lower scoring (indicating less disability) was 
reported by patients of the intervention group, while after 12 months, patients 
of the control group seemed to be less compromised (17.2 vs. 12.1). (However, 
the authors did not report on the statistically significance of the findings.) 
The study comparing RFD plus exercise with exercise alone [52] measured 
the mean functional score, applying the ODI at 3 months (26.03 vs. 28.67), 6 
months (25.38 vs. 27.15), 9 months (25.74 vs. 24.52), and 12 months (24.59 vs. 
25.04). However, the analysis revealed no statistically significant differences 
between both groups throughout the entire observational period.  
The Surgical Efficacy Criteria were used for assessing the outcome “ability 
to work” in 1 study [48]. 
A higher percentage of patients in the intervention group were able to return 
to normal work, compared to patients of the control group (90% vs. 42.5%). 
Accordingly, fewer patients of the intervention group were unable to return 
to normal work (10% vs. 57.5%). The differences between the groups were 
statistically significant.  
 
Daten zur 
Arbeitsfähigkeit wurden 
nicht gesammelt 
im Vergleich zu Plazebo 
ein hoher Unterschied  
in der Funktionalität 
zwischen 6 und  
12 Monaten beobachtbar 
keine erhöhte 
Wirksamkeit als  
add-on Therapie 
Erhöhte Funktionalität 
zwischen 1 und 6 bzw.  
9 Monaten im Vergleich 
zu Steroid-injektionen  
ein höherer Prozentsatz 
der RFD-behandelten 
PatientInnen kann zur 
normalen Arbeit 
zurückkehren 
Clinical effectiveness 
LBI-HTA | 2019 45 
Health-related quality of life 
D0012 – What is the effect of radiofrequency denervation  
on generic health-related quality of life? 
Cervical facet joint pain 
This outcome was reported by 1 study [46].  
However, the authors provided no absolute numbers. They nonetheless stat-
ed that no statistically significant difference between the mean health scores 
of the intervention and the control groups were found throughout the follow-
up period. 
Lumbar facet joint pain 
This outcome was assessed by 1 study [52] using the EQ-5D-3L questionnaire.  
The mean utility score was reported at 3 weeks (0.69 vs. 0.64; p=0.08), 6 weeks 
(0.69 vs. 0.67; p=0.32), 3 months (0.68 vs. 0.69; p=0.85), 6 months (0.73 vs. 
0.71; p=0.42), 9 months (0.72 vs. 0.75; p=0.11), and 12 months (0.73 vs. 0.73; 
p=0.37). However, all analysed time points failed to show a statistically sig-
nificant difference. 
 
D0013 – What is the effect of radiofrequency denervation  
on disease-specific quality of life? 
None of the studies reported on disease-specific quality of life. 
 
Patient satisfaction 
D0017 – Was the use of radiofrequency denervation worthwhile? 
Cervical facet joint pain 
To answer this research question, the outcome ‘satisfaction with treatment’ 
was used, but none of the RCTs reported this outcome. 
Lumbar facet joint pain 
2 studies [52, 53] assessed this outcome using the Global Perceived Effect 
scale.  
In the placebo-controlled trial [53], the satisfaction with the treatment was 
reported, with a mean score of 3.4 in the intervention group compared to a 
score of 3.5 in the control group. Similar results were observed at 2 months 
(3.4 vs. 3.7). The authors reported no statistically significant differences be-
tween the 2 groups throughout the entire follow-up period, yet provided no 
further details. Juch et al. [52] reported the mean patient satisfaction at 3 
months (2.95 vs. 3.26; p=0.34), 6 months (2.96 vs. 3.06; p=0.94), 9 months 
(2.88 vs. 3.13; p=0.91), and 12 months (2.88 vs. 3.01; p=0.32). Thus, no sta-
tistically significant difference between intervention and control was found 
until the end of the 12-month follow-up period. 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Procedure-related complications 
 Adverse events. 
These outcomes were summarised as ‘complications’ in the following chapter 
and in tables, as they are not reported separately within the included studies. 
The outcome ‘complications’ therefore includes direct intervention-related 
side effects, as well as any other negative consequences observed in the fol-
low-up period. 
 
 
6.2 Included studies 
Cervical facet joint pain 
Both RCTs already included for the efficacy analysis were also used to eval-
uate safety [46, 54]. 
The study characteristics and the results of the included studies are displayed 
in Table A-1. The results of the quality assessment of the included studies 
are summarised in Table 7-1, and in the evidence profile in Table A-8. 
Lumbar facet joint pain 
In addition to the 5 studies that had already been included in the clinical ef-
fectiveness assessment, we included 1 RCT with a total of 55 participants 
that compared thermal radiofrequency denervation (26 patients) with pulsed 
dose radiofrequency denervation (29 patients) [63]. The trial was conducted 
in the United States and published in 2016. The patients were included if 
they suffered at least 6 months from low back pain and did not response to 
any conservative treatment. Furthermore, they had to show a positive response 
(>80% pain relief) to 2 diagnostic blocks. 
The mean age of the participants was 51 years; 76% were female. The follow-
up was 48 hours (2 days), during which 10.3% of the thermal radiofrequency 
denervation group and 19.2% of the pulsed dose radiofrequency denervation 
group were lost. 
The study was judged to have a high risk of bias due to possible bias on ac-
count of missing data. 
The study characteristics and the results of the included studies are displayed 
in Table A-2, Table A-3, and Table A-4. The results of the quality assessment 
of the included studies are displayed in Table A-6, Table A-7, and Table A-9.  
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Facet joint syndrome in patients with osteoporosis 
No studies that include patients with osteoporosis and facet joint syndrome 
were identified through the systematic literature search.  
Therefore, results for safety are only presented for lumbar and cervical facet 
joint pain. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is radiofrequency denervation in comparison  
to placebo or steroid injections? 
Cervical facet joint pain 
Complications were reported in 1 placebo-controlled trial [54]: 
At discharge from the hospital, 6 out of 6 (100%) patients who received RFD 
reported adverse events, in comparison to 3 out of 6 (50%) patients in the 
control group. At three months, 50% of the patients in the intervention group 
reported complications, compared to 33.3% of the patients in the respective 
control group.  
Lumbar facet joint pain 
No complications were reported in 4 trials [48, 49, 52, 53]. In 1 trial with 
methylprednisolone injection as the control group, 4 patients of the control 
group suffered from pain after the injection [49]. The same complication 
(post-procedural pain) was documented in 38% of those patients receiving a 
thermal radiofrequency denervation, and in 15% receiving a pulsed dose ra-
diofrequency denervation (p=0.1) [63]. 
C0002 – Are the harms related to dosage or frequency  
of applying radiofrequency denervation? 
A higher percentage reported post-procedural pain in the thermal ablation 
group compared to the patient group that received a pulsed dose radiofre-
quency denervation (38% vs. 15%). However, the result was not statistically 
significant [63]. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer that research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of radiofrequency denervation? 
No evidence was found to answer that research question. 
C0007 – Are radiofrequency denervation, steroid injections,  
injections with local anaesthetic or placebo interventions associated  
with user-dependent harms? 
No evidence was found to answer that research question. 
 
keine Studien zu 
Osteoporose oder 
Facettengelenks-
syndrome 
Komplikationen in  
6 Patienten der 
Interventiongruppe vs.  
3 Patienten der 
Kontrollgruppe 
einzige Komplikation  
bei RFD im Bereich der 
lumbalen 
Facettengelenke: 
Schmerzen nach der 
Intervention 
kein signifikanter 
Unterschied 
beobachtbar 
Veränderungen 
unbekannt 
vulnerable Gruppen 
unbekannt 
anwenderinnenbedingte 
Komplikationen 
unbekannt 
 LBI-HTA | 2019 49 
7 Quality of evidence 
RoB for individual randomised controlled studies was assessed with the re-
vised Cochrane risk of bias tool for randomised trials (RoB 2.0) [3]. Non-ran-
domised controlled trials were evaluated using the risk of bias in non-random-
ised studies of interventions (ROBINS-I) [4]. The RoB assessments for the 
included studies are presented in Table A-5, Table A-6, and Table A-7 in the 
Appendix. 
Regarding the 2 RCTs included for cervical facet joint pain, one was graded 
with a high [46] RoB due to the non-blinding of patients and due to missing 
outcome data, and the second was graded with low RoB [54]. 
Regarding the 5 RCTs included for lumbar facet joint pain, 4 were also graded 
with a high RoB [48, 52, 53, 63] mainly due to the non-blinding of patients 
and caregivers, high loss to FU, and incomplete reporting or measurement 
of outcomes. The non-randomised controlled trial [49] was graded with a se-
rious RoB due to possible confounding.  
No studies investigating RFD in patients with osteoporosis and facet joint 
syndrome were identified. Therefore, no evidence was available to perform a 
GRADE-analysis. 
 
Quality of evidence according to GRADE  
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) [49] for each 
endpoint individually. Each study was rated by 2 independent researchers. 
In case of disagreement a third researcher was involved to solve the differ-
ence. A more detailed list of criteria applied can be found in the recommen-
dations of the GRADE Working Group [49].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect.  
 Moderate = We are moderately confident in the effect estimate:  
The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different. 
 Low = Our confidence in the effect estimate is limited: The true 
effect may be substantially different from the estimate of the effect. 
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below (Table 7-1 and Table 7-2), 
and in the evidence profile in the Appendix (Table A-8 and Table A-9). 
Overall, the strength of evidence for the effectiveness and safety of radiofre-
quency denervation for cervical facet joint pain in comparison to injections 
with local anaesthetics or placebo (sham intervention) is moderate to very 
low.  
  
Einschätzung des 
Biasrisikos mittels  
RoB 2.0 und ROBINS-I 
Hauptgründe:  
fehlende Verblindung 
und unvollständige 
Daten 
Qualität der Evidenz 
mittels GRADE bewertet 
zervikalen 
Facettengelenksde-
nervation: mittlere bis 
sehr niedrige Evidenz 
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There is moderate evidence that RFD compared to placebo  
 might not reduce the pain intensity at 24 months, 
 might not increase the functional status at 24 months, 
 might increase the global improvement at 24 months, 
 might increase complications at 3 months. 
There is low evidence that RFD compared to injections 
 might not increase the pain intensity at 2 months, 
 might not improve the quality of life from 2-12 months. 
There is very low evidence that RFD compared to placebo or injections 
 might increase the global improvement at 12 months. 
Overall, the strength of evidence for the effectiveness and safety of radiofre-
quency denervation for lumbar facet joint pain in comparison to steroid in-
jections or placebo (sham intervention) ranges from high to low.  
There is high evidence that RFD compared to placebo, 
 might reduce the pain intensity at 36 months, 
 might increase the functional status at 36 months, 
 might increase the global improvement at 36 months. 
There is moderate evidence that RFD compared to steroid injections  
or placebo 
 might reduce the pain intensity at 12 months. 
There is moderate evidence that RFD compared with steroid injections 
 might increase the functional status at 6 months, 
 might not increase the global improvement at 6 months 
 might not improve the quality of life up to 12 months. 
There is moderate evidence that RFD compared with placebo 
 might not increase the global improvement at 2 months. 
There is low evidence that RFD compared to steroid injections or placebo 
 might reduce the pain intensity at 6 months, 
 might increase the functional status at 12 months, 
 might increase the global improvement at 12 months, 
 might increase complications from 6-36 months. 
 
 
 
bei lumbaler 
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Table 7-1: Summary of findings table of radiofrequency denervation compared to alternative treatment for patients with chronic neck pain 
Outcome 
Absolute effects 
(explanation) 
Relative effect 
(95% CI) 
Number of participants  
(studies) Quality Comments 
Pain intensity (VAS) at 2 months follow-up IG: 43.9 (22.0) vs. 42.4 (28.6); p=0.87 - 30 (1 RCT) [46] ⨁⨁◯◯ 
LOW a,b 
a higher score 
indicates more pain 
Pain intensity (reduction of at least 30 days 
with intense headache) at 24 months follow-up 
IG: 1/5 (20.0%) vs. CG: 3/5 (60.0%) - 10 (1 RCT) ([54]) ⨁⨁⨁◯ 
MODERATE b 
- 
Functional status at 24 months follow-up No significant differences  
between IG and CG. 
- 10 (1 RCT) [54] ⨁⨁⨁◯ 
MODERATE b 
- 
Global improvement (GPE) at 12 months 
follow-up 
IG: 40%-53.3% vs. CG: 0%-46.7% - 41 (2 RCTs) [46, 54] ⨁◯◯◯ 
VERY LOW a,b,c 
- 
Global improvement (GPE) at 24 months 
follow-up 
IG: 3/5 (60%) vs. 1/6 (16.7%) - 11 (1RCT) [54] ⨁⨁⨁◯ 
MODERATE b 
- 
HRQoL 2- 12 months of follow-up No significant differences in the  
mean health scores between IG and CG. 
- 30 (1 RCT) [46] ⨁⨁◯◯ 
LOW a,b 
- 
Ability to work – not reported - - - - - 
Satisfaction with the treatment – not reported - - - - - 
Complications at 3 months IG: 3/6 (50%) vs. CG: 2/6 (33.3%) - 12 (1RCT) [54] ⨁⨁⨁◯ 
MODERATE b 
- 
 
Abbreviations: VAS (Visual Analogue Scale) ranging from 0 indicating ‘no pain’ to 100 indicating ‘severe pain’;  
GPE (Global Perceived Effect) measured with a 7-point scale ranging from ‘much worse’ to ‘much better’  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect. 
Comments: 
a
 High RoB 
b
 Imprecision due to small sample size 
c
 Inconsistency (comparator either sham procedure or steroid injections/TENS) 
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Table 7-2: Summary of findings table of radiofrequency denervation compared to alternative treatment for patients with chronic back pain 
Outcome Absolute effects Relative effect 
(95% CI) 
Number of participants  
(studies) 
Quality Comments 
Pain intensity (NRS)  
at 12 months follow-up 
No significant differences  
between IG and CG. 
- 311 (2 RCTs) [52, 53] ⨁⨁⨁◯ 
MODERATE a 
 
Pain intensity (VAS)  
at 6 months follow-up 
IG: 1.7-6.0 vs. CG: 2.1-5.8 - 200 (2 RCTs) [47, 48] ⨁⨁◯◯ 
LOW b,c 
A higher score incidates 
more pain. 
Pain intensity (VAS)  
at 36 months follow-up (mean change) 
IG: 2.2 vs. CG: 0.4 - 80 (1 RCT) [47] ⨁⨁⨁⨁ 
HIGH 
A higher score incidates 
more pain. 
Functional status (ODI)  
at 12 months follow-up 
IG: 24.59-31.6 vs. CG: 5.9-25.04 - 331 (2 RCTs) [47, 52] ⨁⨁◯◯ 
LOW b,c 
A lower score indicates 
less disability. 
Functional status (ODI)  
at 36 months follow-up (mean change) 
IG: 8.2 vs.2.9(p=0.007) - 80 (1 RCT) [47] ⨁⨁⨁⨁ 
HIGH 
A lower score indicates 
less disability. 
Functional status (Schober Index)  
at 6 months follow-up 
IG: 8.8 vs. CG: 6.2 (p<0.01) - 80 (1 RCT) [48] ⨁⨁⨁◯ 
MODERATE b 
A lower number 
indicates a reduced 
functional status. 
Global improvement (GPE)  
at 2 months follow-up 
IG: 3.4 (1.0)vs. CG: 3.6 (1.1) - 60 (1 RCT) [53] ⨁⨁⨁◯ 
MODERATE b 
A lower score indicates 
a global improvement. 
Global improvement (success in GPE)  
12 months follow-up 
IG: 37.5%-42.7% vs. CG: 2.5%-39.2% - 331 (2 RCTs) [47, 52] ⨁⨁◯◯ 
LOW b,c 
 
Global improvement (success in GPE)  
36 months follow-up 
IG: 7.5% vs. CG: 0% - 80 (1 RCT) [47] ⨁⨁⨁⨁ 
HIGH 
 
Global improvement (Surgical Efficacy Criteria) 
at 6 months follow-up 
Statistically significant differences  
between IG and CG (p<0.01). 
- 80 (1 RCT) [48] ⨁⨁⨁◯ 
MODERATE b 
 
HRQoL (EQ-5D-3L Questionnaire)  
3 weeks-12 months of follow-up 
No significant differences between IG and CG.  251 (1 RCT) [52] ⨁⨁⨁◯ 
MODERATE b 
 
Ability to work (Surgical Efficacy Criteria)  
at 6 months of follow-up 
Excellent: IG: 25 (62.5%) vs. CG: 5 (12.5%) 
Good: IG: 11 (27.5%) vs. CG: 12 (30%) 
Eligible: IG: 3 (7.5%) vs. CG: 2 (5.0%) 
Poor: IG: 1 (2.5%) vs. CG: 21 (52.5%) 
- 80 (1 RCT) [48] ⨁⨁⨁◯ 
MODERATE b 
 
Satisfaction (GPE)  
at 2 months of follow-up 
IG: 3.4 (1.0) vs. CG: 3.7 (1.3) - 60 (1 RCT) [53] ⨁⨁⨁◯ 
MODERATE b 
 
Satisfaction (GPE)  
at 12 months of follow-up 
IG: 2.88 (2.60-3.16) vs. CG: 3.01 (2.73-3.29); 
p=0.32 
- 251 (1 RCT) [52] ⨁⨁⨁◯ 
MODERATE b 
A lower score indicates 
a higher satisafction. 
Complications; follow-up:  
6-36 months (range) 
IG: 10 vs. CG: 8 - 586 (4 RCT+ 
1 observational study) 
[47-49, 52, 53] 
⨁⨁◯◯ 
LOW c,f 
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Abbreviations: NRS: Numeric Rating Scale ranging from 0 to 10; VAS: Visual Analogue Scale ranging from 0 to 100; ODI: Oswestry Disability Index ranging from 0 to 100;  
GPE: Global Perceived Effect Scale ranging from 1 to 7 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect. 
Comments: 
a
 High RoB in 2 of 2 studies 
b
 High RoB  
c
 Inconsistency due to different comparators 
d
 Significant vs. non-significant differences between studies and time points 
 e
 High RoB due to deviations from intended interventions and bias in the measurement of the outcome 
f
 High RoB in 5 of 5 studies 
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8 Discussion 
Pain originating from the neck or the low back belongs to most commonly 
reported conditions worldwide and is characterised by a long duration of the 
illness and recurrent episodes. The non-surgical intervention radiofrequency 
denervation of the facet joints is a non-permanent technique, which is used 
to suspend/resolve the symptoms based on previous localisation of pain. The 
aims of the project were to assess the clinical efficacy and safety of radio-fre-
quency denervation of the cervical and lumbar facet joint pain, compared to 
alternative non-surgical methods or placebo in patients with or without osteo-
porosis. 
No studies investigating the clinical efficacy and safety of radiofrequency de-
nervation in patients with facet joint syndrome and osteoporosis were identi-
fied by the systematic search. Therefore, only results in people without oste-
oporosis are discussed. 
For assessing the clinical efficacy and safety of radiofrequency denervation 
for cervical facet joint pain, 2 RCTs met the inclusion criteria with a total of 
42 patients (21 of whom received RFD). No statistically significant differences 
were found in the outcomes of pain intensity, functional status, global im-
provement, health-related quality of life, and success of the treatment. Nei-
ther of the 2 studies reported on the outcomes of ability to work or satisfac-
tion with the treatment. Yet, a higher number of patients in the intervention 
group reported complications after discharge from the hospital as well as after 
3 months, among which increased neck pain was mentioned most frequently. 
For assessing the clinical efficacy of radiofrequency denervation for lumbar 
facet joint pain, 4 RCTs and 1 non-randomised controlled trial (NRCT) met 
the inclusion criteria, with 571 patients in total (of which 285 patients re-
ceived RFD). For assessing safety, 1 further RCT comparing thermal RFD 
with pulsed dose RFD was included as well. Thus, the study population for 
evaluating safety included 666 patients (of which 351 received RFD). In re-
gard of pain intensity, functional status and global improvement, inconsistent 
results were reported across the studies. The outcomes of HRQoL and satis-
faction with the treatment failed to show a significant difference between 6 
weeks and 12 months. Ability to work was included in a composite measure 
(surgical efficacy criteria of the spine surgery group) in 1 study and showed 
significant differences at 6 months post intervention. In terms of safety, no 
adverse events were encountered in 3 studies. A single study reported non-
statistically significant differences in the number of patients experiencing 
post-procedural pain. 1 study did not report on adverse events. 
 
Interpretation of findings  
Overall, the level of evidence for the clinical efficacy of radiofrequency dener-
vation for the treatment of cervical facet joint pain is moderate to very low 
for the defined crucial outcomes. The RCT that investigated RFD compared 
to an injection with local anaesthetics was assessed with a high RoB due to 
missing data and deviations from intended intervention. The participants 
had the possibility to receive a second treatment after 8 weeks (repetition of 
the initial treatment) and a third treatment (TENS) after 16 weeks in both 
groups, and thus were non-blinded to the intervention received. Furthermore, 
all relevant efficacy outcome parameters (pain intensity, functional status, 
klinische Wirksamkeit 
und Sicherheit von RFD 
im Bereich der 
zervikalen und lumbalen 
Facettengelenke 
untersucht 
keine Studien RFD  
bei Osteoporose 
PatientInnen vorhanden 
2 RCTs zur zervikalen 
Facettengelenks-
denervation evaluiert 
 
Evidenz zu  
21 RFD PatientInnen 
6 Studien  
(5 RCTs + 1 NRCT)  
zur lumbalen 
Facettengelenks-
denervation bewertet 
 
Evidenz zu  
385 RFD PatientInnen 
 
inkonsistente Ergebnisse 
mittlere bis sehr 
niedrige Stärke der 
Evidenz bei zervikalen 
Facettengelenks-
denervationen aufgrund 
von hohem Biasrisiko 
sowie der Möglichkeit 
des Crossover 
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global improvement and health-related quality of life) did rely on patient 
self-reporting, which is likely to be influenced by the knowledge of having or 
having not received the intervention of interest. 
Furthermore, the strength of evidence was downgraded due to the small sam-
ple size of both included trials, which were not adequately powered to detect 
even considerable differences (e.g., success of the treatment after 8 weeks). 
In summary, there is no robust evidence that radiofrequency denervation of 
cervical facet joints leads to better outcomes than an alternative treatment 
with local injections or placebo.  
With regard to RFD for lumbar facet joint pain, 6 studies (5 RCTs and 1 
NRCT) had been published since the last assessment in 2016 and were con-
sidered within the present update.  
The level of evidence regarding the clinical efficacy of radiofrequency dener-
vation for the treatment of lumbar facet joint pain in these newly identified 
studies ranges from high to low. The reasons for downgrading were high risk 
of bias in the majority of the included trials, and inconsistencies between stud-
ies depending on the comparator used (placebo/sham treatment vs. steroid 
injections). 
There is some evidence that radiofrequency denervation of lumbar facet joints 
leads to better outcomes than alternative treatments or placebo. In the fol-
lowing, different aspects that might have influenced these results are present-
ed. The precise localisation of the source of the pain is a major issue in iden-
tifying those patients who will benefit the most from the intervention of in-
terest. If, however, this premise is not fulfilled, patients enrolled in the study 
are not suffering from the conditions for which they were treated (i.e., facet 
joint-related pain). In turn, the anticipated effect will be diluted and the di-
rection of the effect estimate would be biased towards zero. In this regard, 
the preference of 2 diagnostic blocks performed at different time points have 
been shown to be advantageous compared to only 1. Similarly, the degree of 
the pain relief achieved thereby is important in reducing the amount of false 
positives. For this reason, it seems not surprising that those 2 studies that 
used either 2 diagnostic blocks [47] and/or aimed to achieve a complete or 
near complete reduction of pain for inclusion [47, 48] were successful in ob-
serving/reporting significant differences between the groups in the outcomes 
of pain intensity, functional status, and global improvement.  
 
General discussion points 
The patient population varied significantly between studies, especially with 
regard to the duration of the preceding. Patients were included if they suf-
fered from chronic facet pain for a period of 3 months up to 24 months. This 
variation could have a major impact on the investigated outcomes, as the du-
ration of pain prior to treatment is a known prediction factor of the antici-
pated response [64].  
In terms of age, it was noticeable that older patients (> 70 years) were not 
included in the study populations, although this subgroup would more com-
monly suffer from facet-related pain [65]. Furthermore, patients suffering 
from joint pain due to trauma, malignancies or inflammatory diseases were 
excluded, as were patients experiencing degenerative disorders. Thus, no con-
clusion can be drawn on the effectiveness of RFD under these circumstances. 
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A major point of concern was the possibility of a crossover after a specified 
period in 3 of 8 included studies [46, 52, 53]. Therefore, any comparisons be-
tween groups obtained after that time point have to be considered as biased 
[66]. Although the study authors might have introduced this possibility to 
prevent a loss-to-follow-up due to unresponsiveness, most of the studies en-
countered a high percentage of drop-outs. Some authors [52, 54] solved this 
problem by removing patients lost to follow-up from the dataset. However, 
this approach leads to an overestimation of the treatment response and should 
therefore be avoided [64]. 
Due to the non-permanent nature of the intervention, prolonged follow-up 
periods (>12 months) for investigating the effect of RFD as a primary end-
point seemed to be not meaningful. On the other hand, it would be worth-
while analysing potential co-/post-treatments, as an achieved pain reduction 
might increase the commitment of patients in physical therapies, etc. 
 
Upcoming evidence 
The search in clinical trial registries resulted in 51 relevant hits, of which 8 
ongoing RCTs might provide further data on the efficacy and safety of cervi-
cal (Table A-12) and lumbar radiofrequency denervation (Table A-13), in 
comparison to alternative treatments or placebo (sham treatment). Out of 
these, 1 study (NCT03651804) will particularly investigate the effect of ra-
diofrequency ablation as treatment for posterior element pain from vertebral 
compression fractures. Amongst others, the study (with a primary completion 
date in March 2020) will include patients with osteoporosis.  
 
Limitations of the present report 
First of all, we decided to exclusively include studies with a high level of 
evidence (RCTs and NRCTs), as such high evidence is available.  
Secondly, possibly not all appropriate studies could have been identified, 
although different terms in the systematic literature search were used and 
the manufacturers were contacted for additional studies, but did not respond 
to our request. 
Finally, the efficacy outcomes were measured with different scores across 
studies. As a result, in most cases, only a single study was evaluated in the 
GRADE analysis for a particular outcome at a particular time point, thereby 
reducing the explanatory power of the strength of evidence.  
 
Möglichkeit zusätzlicher 
Behandlungen 
verhindert Aussagen zur 
Effektivität der Therapie 
Langzeitbeobachtung 
erscheinen in Hinblick 
auf zeitlich beschränkten 
Therapieeffekt  
nicht sinnvoll 
Ausblick:  
8 laufende RCTs,  
davon eine Studie mit 
Osteoporose-
patientInnen 
Limitationen:  
nur RCTs 
eingeschlossen; 
möglicherweise 
geeignete Studien 
übersehen  
unterschiedliche 
Messinstrumente bei 
gleichem Endpunkt 
verringern Aussagekraft 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence-based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the assessed technology 
of radiofrequency denervation of the cervical facet joints in patients with 
chronic neck pain is more effective and equally safe in comparison to place-
bo or other non-surgical treatments concerning pain, functional status, glob-
al improvement, health-related quality of life, ability to work, satisfaction with 
the treatment and complications. 
The additional evidence since the 2016 assessment is not sufficient to prove 
that the assessed technology of radiofrequency denervation of the lumbar 
facet joints in patients with chronic low back pain is more effective and 
equally safe in comparison to placebo or other non-surgical treatments con-
cerning pain, functional status, global improvement, health-related quality of 
life, ability to work, satisfaction with the treatment, and complications. 
For patients suffering from facet joint syndrome due to osteoporosis, no ev-
idence was found and therefore no recommendation can be given. 
New study results will potentially influence the effect estimate considerably. 
The re-evaluation is recommended in 2023. 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Cervical facet joints: Results from randomised controlled trials 
Author, year Haspeslagh, 2006 [46] Stovner, 2004 [54] 
Country Netherlands Norway 
Sponsor Not reported Not reported 
Study design RCT RCT 
Number of pts 30 (15 vs. 15) 12 (6 vs. 6) 
Intervention Step_1: Percutaneous facet denervation of the facet joints C3-C6: RF-
lesion of the medial ranches of the posterior primary rami; local 
anaesthetic solution (Lidocaine 2%), 60 sec lesion at 67°C; 
Step_2: If after 8 weeks the headache was not relieved sufficiently: 
Diagnostic cervical segmental nerve blocks at the levels that were most 
likely to conduct an excess of afferent stimuli were performed (at least 
2); if there was an reduction of ≥ 50% of the VAS, an RF lesion adjacent 
to the relevant dorsal root ganglion (DRG) was performed 
Step_3: If no positive diagnostic block or after the RF lesion of the DRG 
and 8 weeks after Step_1 no sufficient headache relief: Transcutaneous 
Electrical Nerve Stimulation (TENS) 
Cervical RF medial branch neurotomies performed on facet joints  
C2-C6: fluoroscopic control, after injection of local anaesthetic,  
3-4 lesions at 85°C for 60 sec 
Comparator Step_1: Blocking the greater occipital nerve (GON):  
injection with local anaesthetics (Bupivacaine 0.5%) 
Step_2: If no sufficient headache relief after 8 weeks, repetition of treatment 
Step_3: If still no sufficient pain relief after 16 weeks: TENS 
Sham procedure: Exactly same operation, except that after local 
anaesthesia, no lesions were given after positioning of the needles. 
Inclusion criteria Patients with cervicogenic headache according to the diagnostic criteria 
of Sjaastad: 20-65 years of age; chronic cervicogenic headache > 2 years; 
initial visual analogue scale (VAS) score of > 50 mm during a pain period; 
significant pain during at least two days per week 
25-65 years of age, severe complaints lasting > 1 year inhibiting 
participation in work or social life, insufficient effect of appropriate 
prophylactic headache medication, cerebral CT or MRI and cervical MRI 
without significant pathology 
Striclty unilateral headache without side-shift 
At least 2 of the following: Reduced range of motion in the neck, 
precipitation of typical headache by palpation or pressure exerted against 
muscle insertions in the occiput or the neck, precipitation of typical 
headache by neck movements or positions, irradiation of pain to 
ipsilateral shoulder or arm 
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Author, year Haspeslagh, 2006 [46] Stovner, 2004 [54] 
Exclusion criteria Patients with previous surgical procedures of the cervical spine; 
coagualiton disturbances; patients who are pregnant; patients with 
multilevel severe degenerative changes at their cervical X-ray; diagnosed 
with post-whiplash syndrome 
Cervical spinal stenosis or disc herniation, previous neck surgery, malignant 
disease, rheumatic or other disease necessitating intake of analgesics, other 
clinically significant disease, clinically significant concomitant headache 
disorder, ongoing or pending litigation for compensation after trauma 
Mean age of patients, yrs, (SD) 47.5 (11.0) vs. 49.1 (12.8) 44.5 (34-52) vs. 52.5 (41-64) (median age and range) 
Sex (% female) 11/15 (73%) v.s 11/15 (73%) 3/6 (50%) vs. 3/6 (50%) 
Duration of pain, yrs 9.7 vs.6.6 5.0 (2-10) vs. 6.0 (2-50) 
(years from diagnosis to inclusion, median and range) 
Follow-up (months) 12 24 
Loss to follow-up, n (%) 4 (26.7%) vs. 5 (33.3%) 1 (16.7%) vs. 0 (0%) 
Primary endpoint Percentage of success at 8 weeks (time point 1) Days with intense pain (defined as the number of days per 2 weeks with 
pain intensity 2 (moderate) or 3 (severe) which would reflect the number 
of days where headache interfered with the function of the patient;  
a meaningful clinical response was defined as a reduction of at least  
30% of days with significant headache) 
Outcomes 
Efficacy 
Pain intensity, mean (SD) Percentage VAS improvinga 
8 weeks: 43.9 (22.0) vs. 42.4 (28.6); p=0.87 
16 weeks: 45.4 (23.9) vs. 24.1 (50.1); p=0.17 
6 months: 41.7 (28.5) vs. 28.0 (49.4); p=0.38 
12 months: 44.4 (16.8) vs. 30.7 (49.9); p=0.34 
Reduction of at least 30 days with intense headache between baseline 
and indicated time point (pain diary) 
3 months: 4/6 (RF) vs. 2/6 (Sham) 
12 months: 1/5 (RF) vs. 3/6 (Sham) 
24 months: 1/5 (RF) vs. 3/5 (Sham) 
Functional status Not reported Change from baseline (range) in % 
3 months: 
Neck flexion/extension: 14 vs. 20 (p=0.9) 
Neck lateral flexion: 10 vs. 4 (p=0.6) 
Neck rotation: 0 vs. 4 (NA) 
Algometry: -24 vs. -19 (p=0.9) 
12 months: 
Neck flexion/extension: 6 vs. 6 (NA) 
Neck lateral flexion: 6 vs. 5 (p=0.6) 
Neck rotation: 9 vs. -14 (p=0.3) 
Algometry: -88 vs. -42 (p=0.1) 
24 months: 
Neck flexion/extension: 14 vs. 8 (p=0.7) 
Neck lateral flexion: -2 vs. 7 (p=0.6) 
Neck rotation: -8 vs.-6 (p=0.9) 
Algometry: 0 vs. -35 (p=0.5) 
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Author, year Haspeslagh, 2006 [46] Stovner, 2004 [54] 
Global improvement Global Perceived Effect (GPE) and/or successful VAS (mean VAS 
reduction of > 20 mm OR 2 points OR 50%): n with success (%) 
8 weeks: 12 (80%) vs. 10 (66.7%); (not statistically significant) 
16 weeks: 10 (66.7%) vs. 8 (53.3%); (not statistically significant) 
12 months: 8 (53.3%) vs. 7 (46.7); (not statistically significant) 
Improved to markedly improved Global Impression of Effect 
3 months: 3/6 (RF) vs. 2/6 (Sham) 
12 months: 2/5 (RF) vs. 0/6 (Sham) 
24 months: 3/5 (RF) vs. 1/6 (Sham) 
Health-related quality of life Mean health scores (detailed results not available): 
No statistically significant difference between the mean health scores of 
both groups at different moments 
Not reported 
Ability to work Not reported Not reported 
Success of the treatment  Global Perceived Effect (GPE) and/or successful VAS (mean  
VAS reduction of > 20 mm OR 2 points OR 50%): n with success (%) 
8 weeks: 12 (80%) vs. 10 (66.7%); (not statistically significant) 
16 weeks: 10 (66.7%) vs. 8 (53.3%); (not statistically significant) 
12 months: 8 (53.3%) vs. 7 (46.7); (not statistically significant) 
Meaningful clinical response (reduction of at least 30% of days  
with significant headache) 
3 months: 4/6 (RF) vs. 1/6 (Sham) 
12 months: 1/5 (RF) vs. 3/6 (Sham) 
24 months: 1/5 (RF) vs. 3/5 (Sham) 
Satisfaction with treatment Not reported Not reported 
Safety 
Complications, n (%) Not reported At discharge from the hospital (1-2 days after the procedure): 
Increased neck pain (4/6 RF group vs. 1/6 Sham group) 
Slightly increased neck pain (1/6 RF vs. 1/6 Sham) 
Headache & nausea (1/6 RF vs. 0/6 Sham) 
Dizziness (0/6 RF vs. 1/6 Sham) 
3 months: 
Worsening of the neck pain (1/6 RF vs. 0/6 Sham) 
Neck tenderness (1/6 RF vs. 0/6 Sham) 
Sensory loss in small neck area (1/6 RF vs. 0/6 Sham) 
Fasciculations in right cheek (0/6 RF vs. 1/6 Sham) 
Acute form of rheumatoid arthritis (0/6 RF vs. 1/6 Sham) 
Abbreviations: VAS (Visual Analogue Scale) ranging from 0 to 100; ODI (Oswestry Disability Index) ranging from 0 indicating no restrictions in daily activities to 100 indicating most restrictions 
in daily activities; GPE (Global Perceived Effect) ranging from -3 indicating much worse to +3 indicating no complaints anymore; HRQoL (Health-related Quality of Life  
Comments: 
a
 Sufficient relief of pain was indicated by a mean VAS reduction of more than 20%. 
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Table A-2: Lumbar facet joints: Radiofrequency denervation vs. other methods: Results from randomised controlled trials 
Author, year Juch, 2017 [52] (Footnote: 3 RCTS) Moussa, 2016 [47] Van Tilburg, 2016 [53] Zhou, 2016 [48] 
Country Netherlands Egypt Netherlands China 
Sponsor Funded by grants from the Netherlands 
Organisation for Health Research and 
Development, the Dutch Society for 
Anesthesiology and the Dutch health 
insurance companies 
No funding was received. No benefits in any form have been 
received from a commercial party 
related directly or indirectly to the 
subject of this article. 
Not reported 
Study design RCT RCT RCT RCT 
Number of pts 251 (facet joint trial [1 RCT] of in total 
681 patients in 3 RCTs): 
125 vs. 126b 
120 (3 groups à 40 patients) 60 (30 vs. 30) 80 (40 vs. 40) 
Intervention Standardised exercise programme  
(8-12 hours) over a 3-month period; 
within 1 week after first exercise: 
radiofrequency denervation after 
injection of 2% lidocaine, RFD lesion 
was made at 90°C for 90 sec;  
co-interventions or recurring RFD 
allowed after 3-month period; over-
the-counter medication was allowed; 
psychological care was provided 
when needed 
Percutaneous RF denervation of the 
medial dorsal branch; lesion created 
at 85°C for 90 sec.; lesions were 
performed at L3-4, L4-5 and  
L5-S1 bilaterallyd 
Percutaneous radiofrequency heat 
lesion at 80°C at 60 sec. (total of 
three steps) into the medial branches 
of the primary dorsal ramus after 
introduction of 2% lidocaine; 
additionally, patients were treated 
with graded activity physiotherapy 
Percutaneaous radiofrquency 
thermocoagulation denervation on 
the lumbar facet joint (at 80°C for  
90 sec. after injection of  
2% lidocaine) 
Comparator A 8- to 12-hour standardised exercise 
programme during a 3-month 
intervention period 
Percutaneous radiofrequency 
coagulation of the facet joint capsule 
(each capsule received two lesions) 
Sham control group (did not receive 
radiofrequency lesioning) 
Sham procedure: Same procedure as 
interventions group except without 
the radiofrequency heat lesion;  
a crossover of the sham group was 
provided after > 3 months, if no 
significant pain relief (decrease of 
NRS ≥ 2) was obtained; additionally, 
patients were treated with graded 
activity physiotherapy 
Injection of betamethasone and  
2% lidocaine into the lumbar  
facet joint 
Inclusion criteria Pain considered to be related to  
facet joint, 18-70 years of age,  
no improvement in symptoms after 
conservative treatment, 1 positive 
diagnostic anesthetic block  
(2% lidocaine) prior to randomisation 
(positive, if the participant reported  
≥ 50% pain reduction within  
30-90 minutes after the block) 
Patients complaining of continuous 
CLBP with or without radiating into 
the upper leg lasting for ≥ 1 year 
without improvement after 3 months 
of conservative treatment (analgesics 
and physiotherapy); clinical 
manifestations suggesting a facet 
origin of pain; initial VAS score of ≥ 7;  
Patients with a history of LBP  
> 3 months; failure of conservative care 
(rest, analgesics and physiotherapy); 
decrease in the Numerical Rating 
Scale for pain of ≥ 2 on a 0 to 10 point 
scale after a test injection at the medial 
branch of the primary dorsal ramus 
with local anaesthesia 
Inclusion criteria based on the  
New Zealand LBP Guide 
Patients with a history of lumbar facet 
joint-related low back pain ≥ 6 months 
Symptoms: Pain of the lower waist, 
hips and buttocks, spastic pain of the 
lower limbs, stiffness of the waist,  
no paresthesia 
Signs: Stiffness of adjacent lumbar 
muscles, pain aggravated by extension, 
no signs of nerve damage or nerve 
root traction 
Diagnostic block: Positive findings 
after test injection with 2% lidocaine, 
pain allevation by 80% 
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Author, year Juch, 2017 [52] (Footnote: 3 RCTS) Moussa, 2016 [47] Van Tilburg, 2016 [53] Zhou, 2016 [48] 
Inclusion criteria 
(continuation) 
 positive diagnostic test blockade: 
achieving complete or near complete 
reduction of pain on the VAS 30 min 
after injection of local anesthetic  
(on two different occations); ≥ 18 years 
 Radiographic findings: Deviation  
of the spinous processes from the 
midline, asymmetrical bilateral facet 
joints or lateral bending and 
asymmetrical shadows of psoas 
major, CT- or MRI-proven lumbar 
facet joint osteoarthritis, narrowing of 
facet joint, sclerosis or hypertrophy, 
loss of articular cartilage or 
periarticular hyperostosis 
Exclusion criteria Pregnancy, severe psychological 
problems, involvement in work-related 
conflicts or claims, BMI > 35, 
anticoagulant drug therapy or 
coagulopathy 
Surgical causes of LBP; patients who 
did not experience complete or near 
complete reduction of LBP after the 
test block; prior lumbar surgery; 
associated major comorbidities; prior 
RF treatment for LBP; presence of 
radicular syndromes; infection at the 
injection site; pregnancy; allergic 
reaction to the local anesthetic; 
patients with possible work 
compensation litigations; mental 
handicap or psychiatric condition 
precluding adequate communication; 
scoring ≥ 50 in the Zung Self-Rating 
Depression Scale. 
Exclusion criteria based on the  
New Zealand LBP Guide 
Lumbar disc herniation, lumbar spinal 
stenosis, spondylolisthesis, specific 
and unspecific inflammations and 
tumors, allergies to local anesthetics, 
pregnancy or lactating, symptomatic 
radiculopathies, uncontrolled medical 
illnesses and any conditions that 
could interfere with the interpretation 
of the outcome assessments 
Mean age of patients, 
yrs, (SD) 
52.98 (11.48) vs. 52.60 (10.79) 56.5 (NA) vs. 58.1 (NA) vs. 55.9 (NA) 65 vs. 58 (median age) 56.5 (8.7) vs. 54.6 (7.5) 
Number of females (%) 65 (55.6%) vs. 60 (51.7%) 31 (77.5%) vs. 29 (72.5%) vs. 27 (67.5%) 16 (3.3%) vs. 18 (60.0%) 17 (42.4%) vs. 19 (47.5%) 
Duration of symptoms, 
months (SD) 
Time since first experience with  
low back pain: Median (range) 
146 (49.8-267.7) vs. 100.3 (36.5-186.3) 
Not reported Duration of low back pain: n (%) 
<6 months: 4 (13.3%) vs. 5 (16.7%) 
6-12 months: 2 (6.7%) vs. 6 (20%) 
12-60 months: 10 (33.3%) vs. 10 (33.3%) 
>60 months: 13 (43.3%) vs. 6 (20%) 
Unknown: 1 (3.3%) vs. 3 (10%) 
24.5 (9.7) vs. 26.4 (10.2) 
Follow-up (months) 12 36 12 6 
Loss to follow-up,  
n (%) 
72 (29%) No dropouts till the evaluation at  
6 months post-procedure; 8%, 13% 
and 20% of patients were lost to 
follow-up at 1, 2 and 3 years follow-up, 
respectively, without comparatively 
significant differences between 
groups (p=0.492) 
0 (0%) 0 (0%) 
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Author, year Juch, 2017 [52] (Footnote: 3 RCTS) Moussa, 2016 [47] Van Tilburg, 2016 [53] Zhou, 2016 [48] 
Primary outcome Pain intensity: Measured on an  
11-point numerical rating scale  
(NRS; a score of 0 indicates no pain; 
10 indicates worst pain imaginable)  
3 months after the intervention 
A predefined mulitdimensional 
combined outcome measure (COM) at 
1-year follow-up comprising a balance 
between changes in VAS, changes in 
daily physical activities (using the 
Oswestry disability index, version 1.0) 
and analgesics consumption 
Decrease in pain using the NRS-11 Half-year efficacy after the treatment 
based on the Surgical Efficacy Criteria 
(1994) of the Spine Surgery Group 
Orthopedic Branch of Chinese Medical 
Association (graded as Excellent, 
Good, Eligible, Poor) 
Outcomes 
Efficacy 
Pain intensity 11-point numeric rating scale (NRS): 
Mean pain intensity score (95% CI)c 
3 weeks: 5.17 (4.73-5.61) vs.  
5.92 (5.58-6.26); p=0.18 
6 weeks: 5.19 (4.76-5.61) vs.  
5.90 (5.53-6.26); p=0.20 
3 months: 5.01 (4.59-5.43) vs.  
5.44 (5.03-5.85); p=0.55 
6 months: 4.61 (4.18-5.04) vs.  
4.84 (4.38-5.30); p=0.91a 
9 months: 4.66 (4.20-5.00) vs.  
4.73 (4.24-5-22); p=0.53a 
12 months: 4.49 (4.00-4.97) vs.  
4.44 (3.94-4.94); p=0.13a 
Mean change in VAS of the back: 
3 months: 6.0 vs. 6.3 vs. 5.4; p=0.481 
6 months: 6.0 vs. 6.1 vs. 2.1; p=0.061 
12 months: 5.8 vs. 6.0 vs. 0.7; p=0.036 
24 months: 2.3 vs. 5.9 vs. 0.5; p=0.026 
36 months: 2.2 vs. 5.9 vs. 0.4; p=0.011 
VAS reduction in the back > 50% n (%): 
3 months: 30 (75) vs. 28 (70) vs.  
23 (57.5); p=0.884 
6 months: 24 (60) v.s 26 (65) vs.  
8 (20); p=0.037 
12 months: 18 (45) vs. 23 (57.5) vs.  
3 (7.5); p=0.026 
24 months: 7 (17.5) vs. 20 (50) vs.  
1 (2.5); p=0.017 
36 months: 5 (12.5) vs. 19 (47.5) vs.  
1 (2.5); p=0.012 
Numercal rating scale (0 to 10):  
NRS (SD) 
1 month: 5.3 (1.8) vs. 5.5 (1.9); p=0.66 
(No detailed results for other time 
points available. However, the authors 
stated that no statistically significant 
differences between the groups 
occured with the passage of time.) 
VAS scores: 
1 week: 1.4 vs. 1.9 
1 month: 1.4 vs. 3.6 
6 months: 1.7 vs. 5.8 
The VAS scores of the patients in the 
denervation group at each time point 
was signifcantly lower than the 
control (p<0.01). 
Functional status Measured by Oswestry Disability 
Index (ODI):  
Mean Functioning Score (95% CI)c 
3 months: 26.03 (23.01-29.06) vs. 
28.67 (26.06-31.84); p=0.17 
6 months: 25.38 (22.45-28.30) vs. 
27.15 (24.07-30.23); p=0.74a 
9 months: 25.74 (22.74-28.73) vs. 
24.52 (21.49-27.54); p=0.21a 
12 months: 24.59 (21.39-27.79) vs. 
25.04 (21.77-28.31); p=0.42a 
Measured by Oswestry Disability 
Index (ODI): Mean Change 
3 months: 44.3 vs. 40.6 vs. 39.8; 
p=0.994 
6 months: 40.3 vs. 38.1 vs. 10.3; 
p=0.042 
12 months: 31.6 vs. 33.9 vs. 5.9; p=0.037 
24 months: 12.3 vs. 29.5 vs. 3.2; p=0.018 
36 months: 8.2 vs. 29.2 vs. 2.9; p=0.007 
Not reported Schober index assessment: 
1 week: 9.0 vs. 8.9; p>0.05 
1 month: 8.6 vs. 7.3; p<0.05 
6 months: 8.8 vs. 6.2; p<0.01 
Global improvement Global Perceived Recovery using GPE 
scale (a score of 1-2 indicates success)c: 
3 weeks: 32/108 vs. 5/101;  
RR: 5.41 (2.29-10.34); p<0.001) 
6 weeks: 35/119 vs. 11/118;  
RR: 2.71 (1.37-4.68); p=0.005 
More than 50% improvement in  
LBP on GPE (n,%): 
3 months: 26 (65) vs. 25 (62.5) vs.  
20 (50); p=0.892 
6 months: 21 (52.5) vs. 23 (57.5) vs.  
6 (15); p=0.048 
Global Perceived Effect scale  
GPE Recovery (SD) 
1 month: 3.3 (1.0) vs. 3.4 (1.2) 
2 months: 3.4 (1.0) vs. 3.6 (1.1) 
(No statistically significant  
difference was found.) 
Surgical Efficacy Criteria of the Spine 
Surgery Group, Orthopedic Branch of 
Chinese Medical Association: 
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71 
Author, year Juch, 2017 [52] (Footnote: 3 RCTS) Moussa, 2016 [47] Van Tilburg, 2016 [53] Zhou, 2016 [48] 
Global improvement 
(continuation) 
3 months: 43/119 vs. 27/114;  
RR=1.35 (0.81-2.05); p=0.24 
6 months: 46/113 vs. 39/108;  
RR=1. 04 (0.64-1.12); p=0.85a 
9 months: 41/106 vs. 42/105;  
RR=0.81 (0.48-0.57); p=0.35a 
12 months: 44/103 vs. 40/102; 
RR=0.90 (0.55-1.33); p=0.65a 
12 months: 15 (37.5) vs. 20 (50) vs.  
1 (2.5); p=0.027 
24 months: 4 (10) vs. 18 (45) vs.  
1 (2.5); p=0.015 
36 months: 3 (7.5) vs. 17 (42.5) vs.  
0 (0); p=0.009 
 6 months: n(%) 
Excellent: 25 (62.5%) vs. 5 (12.5%) 
Good: 11 (27.5%) vs. 12 (30%) 
Eligible: 3 (7.5%) vs. 2 (5.0%) 
Poor: 1 (2.5%) vs. 21 (52.5%) 
Health-related quality 
of life 
Measured by EQ-5D-3L 
Questionnaire: Mean Utility Scorec 
3 weeks: 0.69 vs. 0.64 (p=0.08) 
6 weeks: 0.69 vs. 0.67 (p=0.32) 
3 months: 0.68 vs. 0.69 (p=0.85) 
6 months: 0.73 vs. 0.71 (p=0.42)a 
9 months: 0.72 vs. 0.75 (p=0.11)a 
12 months: 0.73 vs. 0.73 (p=0.37)a 
Not reported Not reported Not reported 
Ability to work Not reported Not reported Not reported Included in the Surgical Efficacy 
Criteria of the Spine Surgery Group, 
Orthopedic Branch of Chinese 
Medical Association: 
6 months: n(%) 
Excellent: 25 (62.5%) vs. 5 (12.5%) 
Good: 11 (27.5%) vs. 12 (30%) 
Eligible: 3 (7.5%) vs. 2 (5.0%) 
Poor: 1 (2.5%) vs. 21 (52.5%) 
Satisfaction with 
treatment 
Assessed with Global Perceived  
Effect scale (GPE):  
Mean patient satisfaction (95% CI)c 
3 months: 2.95 (2.70-3.20) vs.  
3.26 (3.00-3.52); p=0.34 
6 months: 2.96 (2.74-3.17) vs.  
3.06 (2.81-3.31); p=0.94a 
9 months: 2.88 (2.63-3.12) vs.  
3.13 (2.83-3.42); p=0.91a 
12 months: 2.88 (2.60-3.16) vs.  
3.01 (2.73-3.29); p=0.32a 
Not reported Global Perceived Effect scale:  
GPE Satisfaction (SD) 
1 month: 3.4 (1.0) vs. 3.5 (1.2) 
2 months: 3.4 (1.0) vs. 3.7 (1.3) 
(no statistically significant difference 
with the passage of time in 
satisfaction between the groups) 
Not reported 
Safety 
Complications, n (%) No treatment-related adverse  
events were reported during the  
1-year follow-up. 
Not reported No serious adverse events were 
encountered. 
Patients in both groups did not 
develop complications such as nerve 
root injury or back skin anesthesia 
during and after treatment 
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Abbreviations: NRS (Numeric Rating Scale) ranging from 0 indicating no pain to 10 indicating worst pain imaginable; VAS (Visual Analogue Scale) ranging from 0 to 100;  
ODI (Oswestry Disability Index) ranging from 0 indicating no restrictions in daily activities to 100 indicating most restrictions in daily activities; GPE (Global Perceived Effect) ranging from  
1 indicating fully recovered to 7 indicating worse than ever; HRQoL (Health-related Quality of Life; EQ-5D-L (3-level EuroQoL 5D Health Questionnaire ranging from 0 indicating worst 
imaginable health state to 1 indicating best imaginable health state 
Comments: 
a
 Additional treatments/co-interventions possible 
b
 Twelve patients in control group received RFD within first 3 months 
c
 Intention-to-treat analysis 
d
 Intervention of interest was RFD of the facet joint capsule. 
 
Table A-3: Lumbar facet joints: Radiofrequency denervation vs. other RFD method: Results from randomised controlled trials 
Author, year Arsanious, 2016 [63] 
Country United States 
Sponsor No compensation from any companies associated with the procedures or study 
Study design RCT 
Number of pts 55 (26 vs. 29) 
Intervention Thermal radiofrequency ablation (RFA): Local anaesthetic with 1% lidocaine, a 21 G 100 mm needle with 5 mm active tip,  
if optimally positioned, 0.25% bupivacaine was infiltrated, 120 sec. pause, followed by RFA at 80°C for 90 sec 
Comparator Pulsed dose radiofrequency (PDRF): Local anaesthetic with 1% lidocaine, a 21 G 100 mm needle with 5 mmactive tip,  
if optimally positioned, 0.25% bupivacaine was infiltrated, PDRF at 42°C/2 Hz/240 pulses, followed by thermal RFA at 80°C for 90 sec. 
Inclusion criteria Patients with diagnosed back pain from facet joint disease, pain for ≥ 6 months, average pain level of ≥ 4 on a numerical pain scale (NPS)#,  
pain not alleviated with conservative therapy; positive response to 2 diagnostic medial branch blocks (> 80% pain relief for at least  
2 hours with lidocaine and > 4 hours with bupivacaine) 
Exclusion criteria Participation in other trials; patients with poorly controlled systematic diseases including cardiovascular, hepatic, renal, hematologic, 
and/or neurologic conditions, severe depression, coagulopathies, and/or were on anticoagulants; or who had other significant sources  
of chronic pain, complex regional pain syndrome, fibromyalgia, rheumatoid arthritis or chronic fatigue syndrome; patients consuming  
> 2 alcoholic drinks and patients with recreational drug use;  
Mean age of patients, yrs, (SD) 52.4 (8.5) vs. 50.1 (12.1) 
Female (%) 77% vs. 75% 
Mean duration of symptoms, months (SD) Not reported 
Follow-up (months) 2 days (first 48 hours following the procedure) 
Loss to follow-up, n (%) 5 (19.2%) vs. 3 (10.3%) 
Primary outcome Effects on postprocedural pain and the requirement of oral analgesic medication usage in the first 48 hours following the procedure 
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73 
Author, year Arsanious, 2016 [63] 
Outcomes 
Efficacy 
Pain intensity Pain levels: Numeric pain scale: NPS (SD) 
Day 1 (morning): 4.43 (2.9) vs. 2.38 (2.4); p=0.01 
Day1 (afternoon): 4.80 (3.2) vs. 3.08 (2.8); p=0.06 
Day 2 (morning): 3.86 (2.8) vs. 2.31 (2.7); p=0.06 
Day 2 (afternoon): 3.90 (2.7) vs. 2.60 (2.4); p=0.09 
Functional status Not reported 
Global improvement Not reported 
Health-related quality of life Not reported 
Ability to work Not reported 
Satisfaction with treatment Not reported 
Safety 
Complications, n (%) Post-procedural pain (patients using pain medication): 38% vs. 15%; p=0.1 
Abbreviations: NRS (Numeric Rating Scale) ranging from 0 indicating no pain to 10 indicating severe unbearable pain 
 
Table A-4: Lumbar facet joints: Radiofrequency denervation vs. other treatment: Results from non-randomised controlled trials 
Author, year Yasar, 2018 [49] 
Country Turkey 
Sponsor None 
Study design Non-randomised controlled trial 
Number of pts 100 (50 vs. 50) 
Intervention Pulsed radiofrequency denervation at 42°C for 120 sec.  
Comparator Injection of 0.25% bupicacaine + 40 mg methylprednisolone acetate (steroid) into each level 
Inclusion criteria Lower back pain and sciatalgia with normal neurological examination; bilateral pain on facet articulations, in addition to  
lower back pain and sciatalgia, no gain from usual treatment methods, ≥ 3 months of duration for lower back pain and sciatalgia;  
normal radiological findings, except stonisis of the joint space and degeneration of the joint; benefited from diagnostic block with  
local anesthetic agent infiltration to the facets 
Exclusion criteria Not reported 
Mean age of patients, yrs, (SD) 47.4 (11.1) vs. 43.1 (8.35) 
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Author, year Yasar, 2018 [49] 
Female (%) 10 (20%) vs. 16 (32%) 
Mean duration of symptoms, months (SD) Not reported 
Follow-up (months) 12 
Loss to follow-up, n (%) Not reported 
Primary outcome Pain intensitiy measured with the Visual Analogue Scale (VAS) and functional disability measured with the Oswestry Disability Index (ODI) 
Outcomes 
Efficacy 
Pain intensity VAS Score: mean (SD)  
3 months: 2.5 (1) vs. 3.3 (1)  
6 months: 2.3 (1.4) vs. 3.3 (0.9) 
9 months: 2.7 (0.9) vs. 2.5 (1) 
12 months: 3.0 (1.1) vs. 3.0 (1.5) 
Functional status Oswestry Disability Index (ODI): Mean (SD) 
3 months: 18.9 (5.7) vs. 24.1 (8.7)  
6 months: 14.9 (7) vs. 24.8 (9.5) 
9 months: 10.4 (2.8) vs. 12.2 (3.8) 
12 months: 17.2 (6.4) vs. 12.1 (4.4) 
Global improvement Not reported 
Health-related quality of life Not reported 
Ability to work Not reported 
Satisfaction with treatment Not reported 
Safety 
Complications, n (%) No complications were reported; pain after injection occurred in 4 patients. 
Abbreviations: VAS (Visual Analogue Scale) ranging from 0 to 100; ODI (Oswestry Disability Index) ranging from 0 to 100 
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Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differ-
ences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA [53] and in the Guidelines of EUnetHTA [53].  
Table A-5: Risk of bias – Cervical facet joints (randomised studies), RoB 2.0 see [53] 
Trial 
Bias arising from the 
randomisation process 
Bias due to deviations from 
intended interventions 
Bias due to missing 
outcome data 
Bias in measurement  
of the oucome 
Bias in selection  
of the reported result 
Risk of bias – 
study level 
Haspeslagh, 2006 [46] Some concerns1 High2 High3 Low Low High 
Stovner, 2004 [54] Low Low Low Low Low Low 
1
 No information available 
2 
Patients aware of their respective treatment 
3
 Loss to follow-up (26.7% vs. 33.3%) 
 
Table A-6: Risk of bias – Lumbar facet joints (randomised studies), RoB 2.0 see [53] 
Trial 
Bias arising from the 
randomisation process 
Bias due to deviations from 
intended interventions 
Bias due to missing 
outcome data 
Bias in measurement  
of the oucome 
Bias in selection  
of the reported result 
Risk of bias – 
study level 
Juch, 2017 [52]1 Low High2 High3 High4 Low High 
Moussa, 2016 [47] Low Low Low Low Low Low 
Van Tilburg, 2016 [53] Some concerns5 High6 Low Low Some concerns7 High 
Zhou, 2016 [48] Low High8 Low High9 Low HIgh 
RF vs. other method of RF (for safety only) 
Arsanious, 2016 [63] Low Low High10 Low Low High 
 
Comments:  
1 
Evaluation of facet joint study only  
2 
Non-blinding of patients and caregivers 
3 
29% lost to follow-up 
4 
Participants and caregivers were not blinded. 
5 
No random sequence generated 
 
6 
A crossover for the sham group was provided after a minimum period of 3 months if no significant pain relief was obtained. 
7 
Multiple analyses of the data 
8 
Patients and caregivers not blinded 
9 
Non-blinded outcome assessors were aware of the intervention. 
10 
8 patients were lost to FU: IG: 5 (19.2%) vs. CG: 3 (10.3%) 
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Table A-7: Risk of bias of non – randomised studies comparing RF denervation versus steroid injection, ROBINS-I see [3] 
Study  
reference/ID 
Bias due to 
confounding 
Bias selection  
of participants 
into the study 
Bias in 
classification  
of interventione 
Bias due to deviations 
from intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement  
of outcomes 
Bias in selection 
of the reported 
results 
Overall 
bias Comments 
Yasar, 2018 [49] Serious1 Low Low Low Low Moderate2 Low Serious … 
1
 The only demographic characteristics of the patient population described and compared between the two study groups were age, gender, length and weight.  
2
 Outcome was influenced by knowledge of intervention and outcome assessors were aware of intervention. 
 
Table A-8:  Evidence profile: efficacy and safety of Radiofrequency denervation for patients with chronic neck pain 
Quality assessment Number of patients 
Absolute effect 
(SD) 
Certainty Importance Number  
of studies 
Study 
design 
Risk  
of bias Inconsistency Indirectness Impression 
Other  
considerations RFD 
Alternative 
treatments 
Efficacy 
Pain intensity (VAS) at 2 months follow-up 
1 RCT [46] Serious a Not s 
erious 
Not  
serious 
Serious b None 15 15 IG: 43.9 (22.0) vs.  
CG: 42.4 (28.6) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Pain intensity (Reduction of at least 30 days with intense headache) at 24 months follow-up 
1 RCT [54] Not 
serious 
Not  
serious 
Not  
serious 
Serious b None 5 5 IG: 1 (20%) vs.  
CG: 3 (60%) 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Functional status at 24 months of follow-up 
1 RCT [54] Not 
serious 
Not  
serious 
Not  
serious 
Serious b None 5 5 No significant differences 
between IG and CG. 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Global improvement (GPE) at 12 months follow-up 
2 RCTs  
[46, 54] 
Serious a Serious c Not  
serious 
Serious b None 20 21 IG: 40%-53.3% vs.  
CG: 0%-46.7% 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Global improvement (GPE) at 24 months follow-up 
1 RCT [54] Not 
serious 
Not  
serious 
Not  
serious 
Serious b None 5 6 IG: 3 (60%) vs.  
CG: 1 (16.7%) 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
HRQoL 2-12 months of follow-up 
1 RCT [46] Serious a Not  
serious 
Not  
serious 
Serious b None 15 15 No significant differences 
between the IG and CG. 
⨁⨁◯◯ 
LOW 
CRITICAL 
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Quality assessment Number of patients 
Absolute effect 
(SD) Certainty Importance Number  
of studies 
Study 
design 
Risk  
of bias Inconsistency Indirectness Impression 
Other  
considerations RFD 
Alternative 
treatments 
Ability to work – not reported 
- - - - - - - - - - - IMPORTANT 
Satisfaction with the treatment – not reported 
- - - - - - - - - - - IMPORTANT 
Safety 
Complications 2 days to 3 months follow-up 
1 RCT [54] Not 
serious 
Not  
serious 
Not  
serious 
Serious b None 6 6 IG: 9 (150%) vs.  
DG: 5 (83.3%) 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Abbreviations: VAS (Visual Analogue Scale) ranging from 0 to 100; GPE (Global Perceived Effect) ranging from 1 to 7; HRQoL (Health-related Quality of Life) 
Comments: 
a High RoB 
b Imprecision due to small sample size 
c Inconsistency (comparator either sham procedure or steroid injections/TENS) 
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Table A-9: Evidence profile: efficacy and safety of Radiofrequency denervation for patients with chronic back pain 
Quality assessment Number of patients 
Absolute effect Certainty Importance Number  
of studies 
Study 
design 
Risk  
of bias Inconsistency Indirectness Impression 
Other 
considerations RFD 
Alternative 
treatments 
Efficacy 
Pain intensity (NRS) at 12 months follow-up 
2 [52, 53] RCTs Serious a Not serious Not  
serious 
Not  
serious 
None 155 156 No significant differences 
between IG and CG. 
⨁⨁⨁◯ 
Moderate 
CRITICAL 
Pain intensity (VAS) at 6 months follow-up 
2 [47, 48] RCTs Serious b Serious c Not  
serious 
Not  
serious 
None 80 80 IG: 1.7-6.0 vs. CG: 2.1-5.8 ⨁⨁◯◯ 
Low 
CRITICAL 
Pain intensity (VAS) at 36 months follow-up 
1 [47] RCT Not 
serious 
Not serious Not  
serious 
Not  
serious 
None 40 40 IG: 2.2 vs. CG: 0.4 ⨁⨁⨁⨁ 
High 
CRITICAL 
Functional status (ODI) at 12 months follow-up 
2 [47, 52] RCTs Serious b Serious c Not  
serious 
Not  
serious 
None 165 166 IG: 24.59-31.6 vs. CG: 5.9-25.04 ⨁⨁◯◯ 
LOW 
CRITICAL 
Functional status (ODI) at 36 months follow-up 
1 [47] RCT Not 
serious 
Not  
serious 
Not  
serious 
Not  
serious 
None 40 40 IG: 8.2 vs. CG: 2.9 ⨁⨁⨁⨁ 
HIGH 
CRITICAL 
Functional status (Schober Index) at 6 months follow-up 
1 [48] RCT Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 40 40 IG: 8.8 vs. CG: 6.2 (p<0.01) ⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Global improvement (GPE) at 2 months follow-up 
1 [53] RCT Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 30 30 IG: 3.4 vs. CG: 3.6 (p>0.05) ⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Global improvement (success* in GPE) at 12 months follow-up 
2 [47, 52] RCTs Serious b Serious c Not  
serious 
Not  
serious 
None 165 166 IG: 37.5%-42.7% vs.  
CG: 2.5%-29.3% 
⨁⨁◯◯ 
LOW 
CRITICAL 
Global improvement (success* in GPE) at 36 months follow-up 
1 [47] RCT Not 
serious 
Not  
serious 
Not  
serious 
Not  
serious 
None 40 40 IG: 7.5% vs. CG: 0% ⨁⨁⨁⨁ 
HIGH 
CRITICAL 
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Quality assessment Number of patients 
Absolute effect Certainty Importance Number  
of studies 
Study 
design 
Risk  
of bias Inconsistency Indirectness Impression 
Other 
considerations RFD 
Alternative 
treatments 
Global improvement (Surgical Efficacy Criteria) at 6 months follow-up 
1 [48] RCTs Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 40 40 Statistically significant 
differences between  
IG and CG. 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
HRQoL (EQ5D-3L) 3 weeks-12 months follow-up 
1 [52] RCT Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 125 126 No significant differences 
between the mean health 
scores of IG and CG at 
different time points. 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Ability to work (Surgical Efficacy Criteria) at 6 months follow-up 
1 [48] RCT Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 40 40 Excellent: 
IG: 62.5% vs. CG: 2.5% 
Good: IG: 27.5% vs. CG: 30% 
Eligible: IG: 7.5% vs. C: 5.0% 
Poor: 2.5% vs. CG: 52.5% 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Satisfaction with the treatment (GPE) at 2 months follow-up 
1 [53] RCT Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 30 30 IG: 3.4 (1.0) vs. CG: 3.7 (1.3) ⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Satisfaction with the treatment (GPE) at 12 months follow-up 
1 [52] RCT Serious d Not  
serious 
Not  
serious 
Not  
serious 
None 125 126 IG: 2.88 (2.60-3.16) vs. 
 CG: 3.01 (2.73-3.29); p=0.32 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Complications 6-36 months follow-up 
5 [48, 49, 
52, 53, 63] 
RCTs(4) + 
observational 
trials (1) 
Serious e Serious i Not s 
erious 
Not  
serious 
None 311 275 IG: 10 vs. CG: 8 ⨁⨁◯◯ 
LOW 
CRITICAL 
Abbreviations: NRS (Numeric Rating Scale) ranging from 0 to 10; VAS (Visual Analogue Scale) ranging from 0 to 100; ODI (Oswestry Disability Index) ranging from 0 to 100;  
GPE (Global Perceived Effect) ranging from 1 to 7; HRQoL (Health-related Quality of Life) 
Comments:  
a
 High RoB in 2 of 2 studies 
b
 High RoB in 1 of 2 studies 
c
 Inconsistency (comparator either sham procedure  
or steroid injections/TENS) 
 
d
 High RoB  
e
 High RoB in 5 of 5 studies 
f
 Inconclusive results 
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Applicability table 
Table A-10: Summary table characterising the applicability of a body of studies (RFD for cervical facet joint pain) 
Domain Description of applicability of evidence 
Population The total number of patients was 42. The participants had to experiencing cervicogenic  
headache for at least 1 or 2 years. The mean age of the patients ranged from 44.5 to 52.5 years.  
The percentages of female participants were 50% and 73%, respectively. 
Intervention Both RCTs applied a percutaneous RF denervation of the facet joints C2/C3-C6 (67°C-85°C for 60 sec). 
Comparators One RCT compared RFD with an injection of local anaesthetics, the other with  
a placebo/sham treatment. 
Outcomes All outcomes defined as crucial were reported by at least one study (functional status, health-
related quality of life and complications). Both studies reported on the outcomes of pain intensity 
(percentage VAS improving and reduction of at least 30 days with intense headache between 
baseline and indicated time point), global improvement, and success of the treatment (Global 
Perceived Effect and/or successful VAS and meaningful clinical response of a reduction of at least 
30% of days with significant headache). Neither of the two studies reported data on the important 
outcome ability to work. 
Setting The trials were conducted in the Netherlands and in Norway, and published  
in 2004 and 2006, respectively.  
 
Table A-11: Summary table characterising the applicability of a body of studies (RFD for lumbar facet joint pain) 
Domain Description of applicability of evidence 
Population The patient population (n=666) varied considerably between the studies. The participants had  
to suffer from chronic low back pain from at least 3 months to 12 months. The mean age ranged 
from 43-65 years. 20% to 77.5% of the particpants were female. 
Intervention All studies applied percutaneous RF denervation of the facet joints at 80°C-90°C for 60-90 sec., 
except for one study, which performed the intervention at 42°C for 120 sec. One study investigated 
RFD in conjunction with a 3-month exercise programme. 
Comparators In 4 studies, RFD was either compared to placebo/sham treatment or to steroid injections.  
One study used a 3-month exercise programme as a comparator. In 2 studies, conventional RFD  
was compared with either percutaneous RF coagulation of the facet joint capsule or pulsed dose 
radiofrequency (PDRF). 
Outcomes All outcomes defined as crucial for a decision were reported in the included trials. All trials reported 
on the pain intensity (generally measured by VAS or NRS); 4 studies documented the functional 
status and the global improvement of the participant. A single study examined the health-related 
quality of life of the patient. 5 studies reported on complications. The important outcome of ability 
to work was documented by 1 study within a composite measure. 2 studies provided data regarding 
the satisfaction with treatment. 
Setting The trials were conducted in the Netherlands, Turkey, Egypt, China and the United States,  
and published between 2016 and 2018. 
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List of ongoing randomised controlled trials 
Table A-12: List of ongoing randomised controlled trials of RFD for cervical facet joint pain 
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT03066960 
Radiofrequency Neurotomy for Chronic 
Facet Joint-Related Neck Pain 
18-80 years, stable neck pain  
> 12 months, with or without  
unilateral headache 
RF neurotomy Sham 
treatment 
Change in neck function; 
change in pain intensity 
after 6 months 
December 2022 Oslo University 
Hospital,  
St. Olavs Hospital 
Table A-13: List of ongoing randomised controlled trials of RFD for lumbar facet joint pain 
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT03614793 
A Prospective Trial of Cooled Radiofrequency 
Ablation of Medial Branch Nerves vs. Facet 
Joint Injection of Corticosteroid for the 
Treatment of Lumbar Facet Syndrome 
>40 years of age, axial back pain 
for at least 3 months, no response 
to conventional treatment  
MRfFUS ablation 
Cooled RF 
ablation of 
medial branch 
nerves 
Facet joint 
injection of 
corticosteroids 
Proportion of patients 
with a successful 
response 
August 2023 University of 
Utah 
NCT03168802 
MRgFUS and RFA for Treatment of  
Facet-joint Osteoarthritis Low Back Pain 
20-79 years of age, suffering  
from lumbar vertebral facet joint 
syndrome 
MRgFUS 
ablation 
RF ablation Pain score change March 2019 Taipei Medical 
University 
Hospital 
NCT02478437 
A Trial of Cooled RFA of Medial Branch 
Nerves for the Treatment of Lumbar  
Facet Syndrome 
18-79 years, patients with lumbar 
facet syndrome pain for at least  
6 months 
Conventional 
RFA 
Cooled RFA Percent of participants 
who reported ≥50% 
improvement of pain 
August 2018 Northwestern 
University, 
American Pain 
Society 
NCT02942147  
Conventional Radiofrequency, Pulse 
Radiofrequency, and TENS for Lumbar  
Facet Joint Pain 
18 years or older, chronic low  
back pain for at least 3 months 
TENS Conventional  
or Pulse 
Radiofrequency 
Change in Visual 
Analogue Scale 
September 2015 Ege University 
(Turkey) 
NCT03651804  
Radiofrequency Ablation: Treatment for 
Posterior Element Pain from Vertebral 
Compression Fractures 
18-90 years, single level vertebral 
compression fracture, osteo-porotic 
vertebral compression fracture, 
cancer-related patho-logic ‘compres-
sion’ not ‘end-plate’ fracture 
RFA Usual care for 
fractures 
Change in Visual 
Analogue Scale 
March 2020 University of 
California, Davis 
Medical Center 
NCT02148003 
Effect of the Temperature Used in Thermal 
Radiofrequency Ablation 
18 years or older, low back pain  
≥ 3 months 
RFA at 90 
degrees Celsius 
RFA at 80 
degrees Celsius 
Change of pain relief February 2021 The Cleveland 
Clinic 
ISRCTN17868852  
Percutaneous Radiofrequency treatment  
for FACET joint pain  
18 years and older, suggestive facet 
joint pain on lumbar level 
RFD Sham 
treatment 
Pain reduction (NRD) March 2015 Lievensberg 
Hospital, 
Netherlands 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: RF Denervation of facet joints 
Search Date: 20.12.2018 
#1 (facet joint*) (Word variations have been searched) 
#2 MeSH descriptor: [Zygapophyseal Joint] explode all trees 
#3 #1 OR #2 (Word variations have been searched) 
#4 MeSH descriptor: [Denervation] explode all trees 
#5 (denervat*) (Word variations have been searched) 
#6 #6 MeSH descriptor: [Ablation Techniques] explode all trees 
#7 (ablat*) (Word variations have been searched) 
#8 (neurotom*) (Word variations have been searched) 
#9 #4 OR #5 OR #6 OR #7 OR #8 (Word variations have been searched) 
#10 MeSH descriptor: [Radio Waves] explode all trees 
#11 MeSH descriptor: [Pulsed Radiofrequency Treatment] explode all trees 
#12 (radiofrequenc*) (Word variations have been searched) 
#13 #13 (RF):ti,ab,kw 
#14 MeSH descriptor: [Electrocoagulation] explode all trees 
#15 (electrocoag*) (Word variations have been searched) 
#16 (electro-coag*) (Word variations have been searched) 
#17 (thermocoag*) (Word variations have been searched) 
#18 (thermo-coag*) (Word variations have been searched) 
#19 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 (Word variations have been searched) 
#20 #9 AND #19 (Word variations have been searched) 
#21 #3 AND #20 
#22 ((facet* or zygapophyseal or zygapophysial) NEAR ((radiofrequenc* or radio-frequenc* or RF) NEAR 
(denervat* or ablat* or neurotom*))) (Word variations have been searched) 
#23 #21 OR #22 
Total: 94 Hits 
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Search strategy for CRD 
Search Name: RF Denervation of facet joints 
Search Date: 20.12.2018 
#1 MeSH DESCRIPTOR Zygapophyseal Joint EXPLODE ALL TREES 
#2 (facet*) 
#3 MeSH DESCRIPTOR Denervation EXPLODE ALL TREES 
#4 MeSH DESCRIPTOR Radio Waves EXPLODE ALL TREES 
#5 (denervat*) 
#6 MeSH DESCRIPTOR Ablation Techniques EXPLODE ALL TREES 
#7 (ablat*) 
#8 (neurotom*) 
#9 #1 OR #2 
#10 #3 OR #4 OR #5 OR #6 OR #7 OR #8 
#11 #9 AND #10 
#12 (((facet* or zygapophyseal or zygapophysial) NEAR ((radiofrequenc* or radio-frequenc* or RF) NEAR 
(denervat* or ablat* or neurotom*)))) 
#13 #11 OR #12 
Total: 28 Hits 
 
 
Search strategy for Embase 
Search Date: 20.12.2018 
No. Query Results 
#1  'facet joint'/exp 
#2  'facet joint syndrome'/exp  
#3  'facet joint osteoarthritis'/exp 
#4  'facet joint degeneration'/exp    
#5  'facet joint pain'/exp 
#6  'facet joint*':ti,ab,de 
#7  'zygapophyseal joint'/exp 
#8  #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 
#9  'radiofrequency denervation'/exp 
#10  'radiofrequency ablation'/exp 
#11 radiofrequency neurotomy'/exp 
#12 ((radiofrequenc* OR 'radio frequenc*' OR rf) NEAR/5 (denervat* OR ablat* OR neurotom*)):ti,ab,de 
#13 #9 OR #10 OR #11 OR #12 
#14 #8 AND #13 
#15  ((facet* OR zygapophyseal OR zygapophysial) NEAR/5 (radiofrequenc* OR 'radio frequenc*' OR rf) NEAR/5 
(denervat* OR ablat* OR neurotom*)):ti,ab,de 
#16  #14 OR #15 
Total: 475 Hits 
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Search strategy for Medline 
Search Date: 20.12.2018 
No. Query Results 
#1  facet joint*.mp. 
#2  exp Zygapophyseal Joint/ 
#3  1 or 2 
#4  exp DENERVATION/ 
#5  denervat*.mp. 
#6  de-nervat*.mp. 
#7  exp ABLATION TECHNIQUES/ 
#8  ablat*.mp. 
#9  neurotom*.mp. 
#10  4 or 5 or 6 or 7 or 8 or 9 
#11            Radio Waves/ 
#12  exp Pulsed Radiofrequency Treatment/ 
#13  radiofrequenc*.mp. 
#14 radio-frequenc*.mp. 
#15 RF.ti,ab. 
#16 exp ELECTROCOAGULATION/ 
#17 electrocoag*.mp. 
#18 electro-coag*.mp. 
#19 thermocoag*.mp. 
#20 thermo-coag*.mp. 
#21 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
#22 10 and 21 
#23 3 and 22 
#24 ((facet* or zygapophys#al) adj5 ((radiofrequenc* or radio-frequenc* or RF) adj5 (denervat* or ablat* or 
neurotom*))).mp. 
#25 23 or 24 
#26 remove duplicates from 25 
Total: 300 Hits 
 
 
 
  
 
 
 
 
